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ABSTRACT 
EFFECT OF TIBIAL NERVE STIMULATION ON GASTROSOLEUS SPASTICITY: 
A RANDOMIZED CONTROLLED TRIAL 
Department of Physical Medicine and Rehabilitation 
Rahul Jacob Thomas 
MD Physical Medicine and Rehabilitation 
Dr. George Tharion  (guide) 
 
OBJECTIVES 
To compare the effect of repetitive low-threshhold afferent electrical stimulation of the 
Posterior Tibial Nerve against the standard treatment in the management of gastrosoleus 
spasticity in patients surviving cerebrovascular accidents. 
Objective measurement of the change in gastrosoleus spasticity using an electrodiagnostic 
technique, namely the H:M Ratio and comparing the same with the Modified Ashworth Scale 
METHODOLOGY 
Patients attending the weekly stroke clinic were screened and out of the 24 who were enrolled 
in the study, 4 dropped out, leaving 11 patients in the sham stimulation arm and 9 in the 
active intervention arm.  Baseline values of the levels of spasticity as per the Modified 
Ashworth Scale (MAS) and H-max/M-max ratio were recorded. A trained physiotherapist 
administered the electrical stimulation on a daily basis for 2 weeks, with each session lasting 
30 minutes. The electrical stimulation was administered over the Posterior Tibial Nerve at the 
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medial malleolus, on the paretic lower limb. Following 2 weeks of electrical stimulation, 
levels of spasticity were re-assessed using the MAS and H-max/M-max ratio  
RESULTS  
The change in the median H/M ratio value from pre-intervention (0.72) to post-intervention 
(0.56) within the sham arm was not statistically significant (p=0.62). Likewise the change in 
the median H/M ratio value from pre-intervention (0.52) to post-intervention (0.53) in the 
active intervention arm was also not statistically significant (p=0.10).  
For the sham arm, the median percentage increase after the intervention is 7.46% while in the 
active intervention group, it is 27.87%, where the difference between the two arms is not 
statistically significant (p=0.38) 
With regard to the Modified Ashworth Scale scores, clonus which was observed prior to 
starting the intervention was observed even after the two weeks of electrical stimulation. 
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INTRODUCTION 
Spasticity is one of the positive signs of the Upper Motor Neuron Syndrome, seen in 
conditions affecting the cerebral cortex, the brainstem or spinal cord. While there continues 
to be much discussion on the pathophysiology of spasticity, it was first defined by Lance in 
1980 as „a motor disorder characterized by a velocity dependent increase in tonic stretch 
reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the 
stretch reflex, as one component of the upper motor neuron syndrome‟.(1)  Subsequently, 
Young developed the definition further as “a velocity dependent increase of muscle tone with 
exaggerated tendon jerks resulting in hyper-excitability of the stretch reflex in association 
with other features of upper motor neuron syndrome” (2) 
The direct effects of spasticity are pain, weakness, muscle atrophy, exaggerated deep tendon 
reflexes. Secondarily, it can lead to development of abnormal posture, contractures, 
decreased range of motion. This in turn can lead to functional impairment in performance of 
activities of daily living, decreased quality of life and thus significantly affect the 
rehabilitation potential of a patient with spasticity. The only advantage that spasticity may 
have, may be preventing joints in the lower limb from buckling during standing, walking or 
transferring the patient, and preventing the development of Deep Vein Thrombosis.(3) 
In cerebrovascular accidents or strokes, the onset of spasticity is highly variable, with reports 
of about 30% of patients affected within the first few days or weeks. Within 6 weeks, around 
25% of patients have been observed to have features of spasticity. In the lower limbs, 
adduction and extension of the knee with equinovarus foot is the most observed pattern. (4) 
Prevalence of spasticity after stroke have been observed to be highly variable, with estimates 
ranging  from 4% to 42.6%, with prevalence of spasticity severe enough to cause disability, 
2 
 
ranging from 2% to 13%. Studies done on spasticity in different phases following a stroke 
revealed a prevalence of  4% to 27% in the acute phase ( 1 to 4 weeks post-stroke), 19% to 
26.7% in the postacute phase (1to 3 months following stroke) and 17% to 42.6% among those 
in the chronic stage greater than 3 months following the stroke.(5) 
Diagnoses and assessment of outcomes following interventions for spasticity include many 
scales or tools.As there is no uniform definition in place for Poststroke spasticity (PSS) that 
can be used across various research settings, associated with difficulties in the validation of 
assessment tools, the evaluation and appropriate management of spasticity have posed a 
complex challenge. While some assessment scales are subjective, others are more useful for 
objective measures of increments in the degree of spasticity. The most common used tool in 
the clinical assessment of spasticity is the Modified Ashworth‟s scale. However, due to its 
subjective nature, more objective measures have been devised, including some using 
electrophysiology, measures of range of motion and angular acceleration about a joint. The 
evaluation also includes measures of functional ability such as the Modified Rankin Scale, 
Barthel Index and Disability Assessment Scales. It is important to know the level of disability 
or functional limitation a given tool will assess along with its benefits and shortcomings. 
Quantitative methods including electrophysiologic, imaging methods and biomechanical 
techniques supplement more traditional measures in assessing the abnormal activity produced 
by a given spastic muscle. The accurate assessment and evaluation of spasticity is important 
in setting treatment goals for patients and care-takers alike. This in turn facilitates co-
operation, enhances motivation and helps management of their expectations in favourably 
affecting the patient‟s rehabilitation.  It also plays an important role in scaling of achievable 
goals, organization, focus and clarification of the aims of the rehabilitative process. (6) 
The methods used to evaluate spasticity generally fall into three groups – those that assess 
resistance to passive muscle stretch, neurophysiological tests and scales of functional 
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outcome. The Modified Ashworth Scale is one the most widely used test for the evaluation of 
muscle spasticity. This scale however has some significant limitations. Upper motor neuron 
lesion hypertonia is a result of a combination of alterations in viscoelastic properties of 
muscle and spasticity which eventually lead to the formation of fixed muscle contractures.(7) 
The Modified Ashworth Scale cannot reliably differentiate these aspects of hypertonia. The 
intra-rater and inter-rater reliability of this scale in evaluating lower limb spasticity remains 
questionable. (8)(9)The lack of standardisation of test conditions in which the Modified 
Ashworth Scale must be conducted is another limitation of this scale. While some clinicians 
measure muscle tone from a resting state without prior stretch, others recommend extension 
and flexion before noting the actual measurement. This can lead to measurement errors as 
stretch reflex excitability in the resting state may vary from that in the activated muscle.(10) 
The method of scoring severity of spasticity also remains a problem with the Modified 
Ashworth Scale. This is predominantly because it is dependent on the examiner‟s subjective 
impression of the degree of the resistance to passive muscle stretch.(11) 
It is in view of the above mentioned limitations of the Modified Ashworth Scale that an 
additional tool was used in the measurement of change in spasticity following the 
intervention of Posterior Tibial nerve electrical stimulation.  
Muscle spasticity has been attributed to numerous neurophysiological alterations in the 
segmental spinal circuitry. They include heightened excitability of the α motor neurones, 
reduction in presynaptic and reciprocal inhibition, and decreased 1A afferent facilitation. (12) 
Excitability of the α motor neurones as measured by the Hoffman reflex (H reflex), has been 
shown to corroborate with the clinically observed elevation in the myotactic stretch reflex 
activity,(13) and to differentiate spasticity from normal muscle tone.(14) The ratio of the 
maximum H reflex amplitude to the maximum amplitude of the compound motor action 
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potential of the soleus muscle have been demonstrated to be reliable measures of α motor 
neuron excitability.(15) Although this measure of spasticity has not been widely accepted in 
clinical practice due to time constraints, need for expensive, special equipment and expertise, 
they are important objective tests that may be used in the validation of other outcome 
measures on muscle spasticity. With this evidence, the H-max : M-max ratio was considered 
for assessing the change in spasticity following electrical stimulation. 
Treatment options for spasticity involves the removal of noxious stimuli, orthopaedic or 
surgical interventions, appropriate positioning of the patient, use of casts or splints, 
pharmacological agents, chemo-denervation, Botulinum Toxin injections, physical modalities 
and electrical stimulation. In this study, the effect of a non-invasive method of electrical 
stimulation of the posterior Tibial nerve on spasticity of the Gastrosoleus muscle was 
evaluated. The effect of low threshold afferent input on the reduction of ongoing activity 
within interneurons and eventually on the alpha motoneuronsvia spinal segmental, 
propriospinal or supraspinal pathways has been extensively studied. (16) Subsequent studies 
have propounded the various mechanisms by which electrical stimulation brings about the 
neuromodulation required for reduction in levels of spasticity. Electrical stimulation 
administered with a reasonably priced device could be then sent to the patient‟s home to 
continue the stimulation. While being non-invasive, electrical stimulation would have a two-
fold advantage over medication in terms of the levels of sedation and cost benefits in long-
term management of spasticity. 
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AIMS & OBJECTIVES 
To objectively measure the effect of electrical stimulation of posterior Tibial nerve on 
gastrosoleus spasticity using an indigenous hand-held machine. 
 To compare the effect of repetitive low-threshhold afferent electrical stimulation 
of the Posterior Tibial Nerve against the standard treatment in the management of 
gastrosoleus spasticity in patients surviving cerebrovascular accidents. 
 
  Objective measurement of the change in gastrosoleus spasticity using an 
electrodiagnostic technique, namely the H:M Ratio and comparing the same with 
the Modified Ashworth Scale 
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JUSTIFICATION FOR THE STUDY 
I. COST & ADVERSE EFFECTS ASSOCIATED WITH ANTI-SPASTICITY 
DRUGS  
The most commonly used oral drugs for the management of spasticity are 
Baclofen, Diazepam and Tizanidine. A formal cost-anaysis of the average 
monthly expense on anti-spasticity medication for a stroke patient was beyond the 
scope of this study. However to provide an alternative therapy or one which can 
reduce the amount spent on anti-spastic medication, we considered electrical 
stimulation at a convenient location on the body where the Posterior Tibial nerve 
could to stimulated. Other commonly used parenteral medication like Botulinum 
toxin are expensive, while the cheaper Phenol for chemodenervation can lead to 
side-effects of sensory dysaesthesia.  
Electrical stimulation used in a previous study to manage bladder hypertonicity 
had favourable results without any adverse side-effects. This was the rationale for 
considering electrical stimulation in alleviating gastrocsoleus spasticity, 
commonly seen among patients who survived a cerebrovascular accident. 
 
II. THE NEED FOR AN OBJECTIVE MEASURE OF SPASTICITY WHICH CAN 
BE EFFECTIVELY MONITORED 
The most commonly used clinical scale of measuring spasticity is the modified 
Ashworth scale (MAS). However this scale is subjective with inter and intra-rater 
variability. A more precise and quantifiable measure was necessary to monitor 
therapy and progress of the patient. It was with this objective that the 
Hmax/Mmax ratio was chosen. 
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REVIEW OF LITERATURE 
Spasticity is considered part of a broader “Upper Motor Neuron Syndrome” comprising 
weakness, decreased motor control with respect to speed, accuracy and dexterity, loss of 
precise motor control, a positive Babinski sign and increased muscle tone associated with 
hyperactive stretch reflexes.(17) The Upper Motor Neurons originate in the primary motor 
cortex (precentral gyrus of cerebrum) and their axons form the corticospinal and 
corticobulbar tracts.  
In 1980, Lance defined spasticity as “a motor disorder characterized by a velocity-dependent 
increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from 
hyperexcitability of the stretch reflex, as one component of the upper motor neuron 
syndrome.”(18) 
There are multiple factors that affect spasticity and it is the loss of balance between the 
various excitatory and inhibitory inputs into the alpha motor neuron that leads to the clinical 
presentation of spasticity. The loss of balance stems from changes in the way the spinal alpha 
motor neuron handles afferent impulses from proprioceptive, exteroceptive, and 
suprasegmental descending input sources.(19) 
In this this study, the effects of spasticity as the result of a cerebrovascular accident have 
been evaluated. 
PATHOPHYSIOLOGY OF CEREBROVASCULAR ACCIDENTS 
The two major categories of damage to brain tissue in cerebrovasculare damage are Ischemia 
and hemorrhage. Ischemia implies a lack of blood flow to the brain, depriving it of nutrition 
and oxygen. Hemorrhage is the release of blood into the brain and the extravascular regions 
within the cranium. Hemorrhage destroys brain tissue by severing off connecting pathways 
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and causing localized or generalized pressure injury to brain tissue. The ensuing spillage of 
biochemical substances released during and after hemorrhage can adversely afflict vascular 
and parenchymal tissue in its vicinity. 
ISCHEMIA 
There are three mechanisms that lead to ischemia, namely thrombosis, embolism and 
decreased systemic perfusion. Obstruction of blood flow can be either due to localised 
occlusive processes in the case of a thrombus forming within a vessel supplying the brain, or 
due to material originating from a proximal site such as the heart. Systemic hypoperfusion is 
the inadequate supply of blood to the entire body or systemic circulation. Organs such as the 
brain with a high metabolic demand for the oxygen and nutrients supplied in its blood 
perfusion can be adversely affected when the systemic supply is compromised.  
THROMBOSIS 
Thrombosis refers to an occlusive process within the lumen of one or more blood vessels 
leading to obstruction of blood flow to the brain.  The most common type of vascular 
pathology causing occlusion of the artery is atherosclerosis wherein overgrowth of fibrous 
and muscular tissues in the subintima, coupled with fatty plaque formation encroach the 
lumen. 
Atherosclerosis commonly affects large extracranialand intracranial arteries. Primary 
haematological problems such as polycythemia, thrombocytois or a systemic hypercoagulable 
state can promote the formation of atheromatous plaques, often referred to as 
microatheromas. 
Less common pathologies affecting the vascular system leading to vessel occlusion include 
(1) fibromuscular dysplasia, a hypertrophy of medial and intimal elements, which in turn 
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impedes vessel contractility and luminal size ; (2) arteritis, such as Takayasu and giant-cell 
arteritis are a result of inflammatory diseases targeting blood vessels ; (3) dissection of the 
vessel wall, with temporary obstruction of the vessel by luminal or extra-luminal thrombi  ; 
(4) hemorrhage into a plaque compromising the lumen and hence the blood flow. Dilatation 
of blood vessels may also alter the local flow of blood, leading to formation of clots in the 
dilated segments. 
EMBOLISM 
Material formed elsewhere in the vascular system may lodge within the lumen of an artery 
and obstruct blood flow to distal regions. The obstruction may be transient or prolonged for 
hours or days before flowing distally. This obstruction is not caused by a localized process 
but originates proximally, most often from the heart, major arteries such as the aorta, the 
carotid arteries and the vertebral arteries, and from systemic veins. Cardiac causes are mainly 
due to valvular dysfunction and from clots or tumors within the atrial or ventricular 
chambers. Clots generated within the systemic veins may enter the circulation to the brain via 
cardiac defects such as an atrial septal defect or a patent foramen ovale, in a process termed 
paradoxical embolism. Rarely, air, fat, plaque material, foreign material from injected drugs, 
bacteria and metastatic tumor tissue can enter the vascular system and occlude cerebral 
arteries. 
DECREASED SYSTEMIC PERFUSION 
Diminished systemic perfusion to the brain parenchyma may be caused by low systemic 
blood pressure. Problems with myocardial contractility, often due of myocardial infarction or 
an arrhythmia and systemic hypotension due to blood loss or septicaemia are the most 
common causes of systemic hypoperfusion. This can dramatically affect border zones or so-
called water-shed areas at the peripheries of major vascular territories.   
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DAMAGE CAUSED BY ISCHEMIA 
The injury caused in the brain parenchyma may be temporary or permanent, with the latter 
being termed as an infarction.  Capillaries and blood vessels within this infarcted tissue may 
also be injured leading to a hemorrhagic infarction. Injuries may lead to edema during the 
hours and days after a stroke. Glial scars form with macrophages gradually ingesting necrotic 
tissue debris in the chronic phase, resulting in shrinkage of the infarcted parenchyma or 
development of a cavity.  
HEMORRHAGE 
Hemorrhage may be further classified as subarachnoid, intracerebral, subdural and epidural. 
These subtypes each have a different aetiology, a different set of clinical sequelae and a 
different plan of management. 
SUBARACHNOID HEMORRHAGE 
In a subarachnoid hemorrhage, blood leaks out of the vasculature, on to the surface of the 
brain and subsequently disseminates fast via the cerebrospinal fluid pathway to spaces. 
Aneurysms or arteriovenous malformations, bleeding diatheses and trauma are the most 
frequent causes of a subarachnoid hemorrhage. The sudden and rapid release of blood into 
the cranial cavity can elevate the intracranial pressure faster than other causes of bleeding. 
This blood often carries substances promoting vasoconstriction of basal arteries that are 
washed in cerebrospinal fluid. 
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INTRACEREBRAL HEMORRHAGE 
Bleeding that occurs directly into the brain substance, often as a result of hypertension 
damaging small intracerebral arterioles is termed as intracerebral or parenchymal 
hemorrhage. Bleeding diatheses as a result of iatrogenic anticoagulant prescriptions, trauma, 
drugs, vascular malformations and vasculopathies such as cerebral amyloid angiopathy may 
also lead to parenchymal bleeding. The degree of damage depends on the location, velocity, 
volume and pressure of hemorrhage.   
 
PATHOPHYSIOLOGY OF SPASTICITY 
Spasticity can be generally attributed to the loss of suprasegmental control over the spinal 
cord reflexes. (20) The supraspinal regions can be from altered input as a result of imbalance 
of inputs from reticulospinal and other descending pathways to the motor and interneuronal 
circuits of the spinal cord, and the absence of an intact corticospinal system. Lesions 
involving areas 4 and 6 of the cerebral cortex have shown to cause paresis and increased 
muscle tone.(21) Interruption of the reticulospinal tracts have also been shown to cause 
spasticity. (22)There is evidence that the descending tracts directly modulate not only the 
afferent limb of the peripheral reflex arc, but also the anterior horn cells associated with 
them.(23) 
THE MUSCLE SPINDLE: Enclosed within the bulk of the muscle are stretch receptors 
known as muscle spindles. They convey information on the level of stretch experienced by 
the entire muscle, to the central nervous system. Unlike the extrafusal muscle fibres that are 
attached to the tendons at either end of a muscle these intrafusal muscle fibres are spindle-
shaped, not attached to the musculo-tendinous ends of the muscle but enclosed in connective 
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tissue within the bulk of the muscle. (Fig. 1) They consist of two types of fibres: (i) Nuclear 
Chain Fibres which have their nuclei arranged in a linear fashion along the long axis of the 
muscle fiber and sensitive to sustained stretch. (ii)Nuclear Bag Fibres which have their nuclei 
arranged in a collection at the centre of the muscle fibre and mainly sense the onset of stretch. 
(Fig. 2) Both sets of fibres however, will respond to rapid stretch. These fibres transmit 
information to the central nervous system via large myelinated Ia primary sensory or afferent 
nerve fibres with annulospiral endings. There are secondary sensory afferent neurons with 
flower spray endings which also transmit information on stretch of the muscle fibres to the 
central nervous system. Together the primary and secondary sensory nerve fibres enter the 
dorsal horn of the grey matter within the spinal cord. The rate at which they transmit 
impulses into the spinal cord is directly proportional to the amount of stretch experienced by 
the nuclear chain and bag muscle fibres. The sensory neurons to which they transmit 
information, synapse with Gamma Motor Neurons and Alpha Motor Neurons which send 
efferent nerve fibres to the intrafusal fibres and the extrafusal fibres respectively. Stimulatory 
impulses from the Gamma Motor Neurons are responsible for contraction of the intrafusal 
muscle fibres only and cannot cause contraction of the extrafusal fibres and the entire muscle. 
Extrafusal muscle fibres contract when stimulated by efferent fibres from the Alpha Motor 
Neuron in the spinal grey matter.  The stretch reflex consists of sensory impulses transmitted 
by the stretching of the intrafusal muscle fibres, causing efferent fibres from the alpha motor 
neuron to protectively contract the extrafusal muscle fibres and prevent them from being torn 
by excessive stretching. The protective contraction of the extrafusal fibres will eventually 
cause a slack in the stretch of the intrafusal muscle spindle and prevent further transmission 
of sensory information to the spinal cord. Gamma motor neurons must hence transmit 
efferent impulses to the intrafusal fibres to maintain their tone. Upper motor neurons at the 
supra-spinal level control both the Gamma and Alpha Motor neurons by co-stimulation. 
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Figure 1 Connections of Extrafusal and Intrafusal Fibres to the Spinal Cord 
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Figure 2 Fibres Emerging From the Muscle Spindle 
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The activity of Ia and II afferent fibres from the muscle spindle to the alpha and gamma 
motor neurons, helps control the amount of stretch and contraction of the muscle. This 
sensory information is modulated by suprasegmental control. Increased reflex excitability 
could be due to either excessive excitation or to decreased inhibition at the segmental level. 
The suprasegmental control consists of the following (Fig.3) : 
CERBRAL CORTEX – it is essential in sending analytical and command motor signals and 
executes the same from: 
a. Frontal motor area which forms the corticospinal or pyramidal pathway 
b. Premotor and supplementary motor cortices  which sequence and modulate all 
voluntary movements 
c. Prefrontal cortex which projects to the premotor and supplementary motor areas to 
help with planning and initiation of willed activity 
d. Parietal cortical areas (5,7) which play an important role in guidance of movement. 
e. Association areas concerned with conscious (visual, auditory, tactile) or subconscious 
(proprioceptive) information also guides the motor system. 
SUBCORTICAL CENTERS: basal ganglia (pallidum, subthalamic nucleus, striatum, 
substantianigra) and the cerebellum help in maintenance of tone, posture and co-ordination 
of movement. 
BRAINSTEM is the major relay station which through its nuclei especially in the pons, 
medullary reticular nuclei, vestibular and red nuclei, influence muscle stretch reflexes, 
posture, and repetitive movements. 
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Figure 3 Supraspinal Pathways Involved in Spasticity 
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GOLGI TENDON ORGANS (GTOs): Golgi Tendon Organs help the muscle spindle fibres 
as sensory receptors that transmit information regarding muscle stretch, to the central nervous 
system. They are mechanoreceptors in the myotendinous and myoaponeurotic junctions of 
the muscle. At one end, they contain Ib afferent fibres intertwined with collagen bundles in 
continuity with the tendon or aponeurosis. At the opposite end, they are connected with a 
fascicle of 5-25 muscle fibres from several motor units. When muscle tension exceeds a 
threshold level, they inhibit further contraction and muscle then relaxes. They send their 
information to inhibitory interneurons which in turn can decrease the rate of alpha motor 
neuron firing and the amount of extrafusal muscle contraction. Golgi tendon organs and their 
Ib afferents are more susceptible to high velocity low amplitude manipulation.. They also 
inhibit the firing of antagonist spindles by suppression of Ia interneurons, thus protecting the 
antagonist muscle from firing and injuring the agonist muscle.(19) 
 
SPINAL INTERNEURONS 
Spinal Interneurons also play a crucial role in modulation of presynaptic and reciprocal Ia 
fibres by the release of Gamma Aminobutyric acid (GABA).(24) These inhibitory spinal 
interneurons are controlled in part by the corticospinal and the spinal cerebellar tract. The 
loss of Renshaw cell inhibition is another factor affecting the development of spasticity, 
although the extent of its contribution is not known.(19)The Interneuron systems of the 
stretch reflex are discussed below (Fig. 4): 
1. Renshaw cells are located in the lamina VII of ventral horn medial to the 
motorneurons. Collaterals from an alpha motoneuron axon excite the Renshaw cell 
which in turn inhibits the same and other motorneurons innervating synergistic 
muscles. This motoneuron pathway of inhibition forms a negative feedback circuit 
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and is also called „recurrent inhibition‟. (25)Renshaw cells also inhibit gamma 
motoneurons and 1a inhibitory interneurons. (26) 
2. Reciprocal 1a inhibition: while the stretch of a muscle activates 1a afferent fibres to 
produce monosynaptic excitation of homonymous alpha motoneurons, there also 
occurs disynaptic inhibition of alpha motoneurons innervating antagonist muscles. 
3. Inhibition from Group II Afferents: fibres from secondary spindle can produce flexion 
reflex by excitation of flexor alpha motoneurons while inhibiting the extensor 
motoneurons. 
4. Non-reciprocal Ib Inhibition: Ib afferent fibres carry impulses from the Golgi tendon 
organs to inhibitory interneurons which in turn synapse with alpha motoneurons 
supplying both homonymous and heteronymous muscles. Ib non-reciprocal inhibition 
is part of a complex system regulating muscle tension controlling posture and 
movement with diverse segmental and supraspinal inputs. 
5. Presynaptic Inhibition: Amplitude of the excitatory post-synaptic potential (EPSP) 
generated in a motoneuron by Ia afferent stimulation diminishes if specific 
interneurons depolarize this Ia afferent fibre through an axo-axonic synapse. It is a 
means of automatic suppression of unimportant afferent information. 
6. Flexor Reflex Afferents: Nociceptive or simple pain reflex produces contraction of 
flexor muscle of a limb (withdrawal) and crossed extensor reflex of opposite limb. 
Polysynaptic connections between flexor reflex afferents (FRA), interneurons and 
motoneurons mediate this reflex. 
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  Figure 4 Interneuronal Pathways Ways in the Spinal Cord 
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EXCITATORY PATHWAYS IN SPINAL CONTROL OF SPASTICITY 
1. Increased Fusimotor Drive – erstwhile theory which has now been discredited. 
 
2. Primary Hyperexcitability of alpha motoneurons following upper motor neuron 
lesions: Voltage dependent, persistent inward Calcium and Sodium currents amplify 
and prolong the response of motoneuron to synaptic excitation. They produce 
prolonged depolarizations (plateau potentials) when outward currents are reduced or 
the calcium channels are facilitated by specific neurotransmitters. Eg. Serotonergic or 
noradrenergic innervations. The possible contribution of plateau potentials to 
spasticity in humans is not very evident as it is difficult to demonstrate the existence 
of such intrinsic membrane properties in the intact organism.(27) 
 
3. Enhanced Cutaneous Reflexes: Flexor or withdrawal cutaneous reflexes have been 
shown to be enhanced in spasticity. Aside from ascending tracts formed by long 
axons, the dorsal horn neurons also give rise to short propriospinal axons that 
innervate motor neurons of the cord. The latter are influenced by descending 
reticulospinal tract (RST) and in lesions of the spinal cord, the normal gating 
mechanisms in the dorsal horn are disrupted, causing pain to be experienced by rather 
innocuous stimuli. These altered segmental inputs, helped by failure of presynaptic 
inhibition, results in hyperactivity in the alpha motoneurons, experienced as pain 
associated with spasticity. 
At the level of the spinal cord, the mechanisms attributed to development of spasticity can be 
divided into PreSynaptic and PostSynaptic pathways. Presynaptic pathways can be further 
elaborated as: (i) presynaptic IA inhibition & (ii) post-activation depression. 
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 Post-Synaptic pathways can be further classified as:  
(i) Ib Inhibition 
(ii) Recurrent inhibition 
(iii) Disynaptic Reciprocal Ia Inhibition. 
 Increased stretch-evoked synaptic excitation of motor neuron are also 
attributed as a cause of spasticity and three causes have been propounded for 
the role of excitatory interneurons in the same: (i) collateral sprouting (ii) 
denervation hypersensitivity or (iii) diminished presynaptic inhibition.(28) 
 
NEUROTRANSMITTERS IN SPASTICITY:  Impulses from the various segmental and 
supra-segmental centres influence alpha motoneuronvia Excitatory Post Synaptic Potentials 
(EPSPs) and inhibitory post-synaptic potentials (IPSPs). While the neurotransmitter agents 
responsible have not yet been clearly defined, aspartate and glutamate are thought to be 
responsible for EPSPs and glycine and GABA for IPSPs. Inhibition by remote or presynaptic 
inputs to the motoneuron pool, such as Ia afferent nerve, cutaneous nerve, are mediated by 
Gamma-Aminobutyric Acid (GABA).(29) 
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EVALUATION OF SPASTICITY 
CLINICAL EVALUATION 
The clinical evaluation of spasticity should be based on the following tenets(30): 
 Differentiating Spasticity from increased muscle tone resulting from other causes 
 Detecting the presence of factors that aggravate spasticity 
 Quantifying spasticity 
 Assessing its effect on functional ability 
VERIFYING SPASTICITY 
Spasticity has characteristic features that help differentiate it from rigidity, catatonia, 
gegenhalten or contractures which also cause increased muscle tone: 
Velocity Dependence: The faster the muscle is stretched, greater is the muscle 
resistance. 
„Clasp-knife‟ phenomenon: After an initial resistance to movement, the spastic limb 
suddenly gives way, much like that of a folding knife blade. As contractures set in, 
this phenomenon is replaced by solid non-elastic resistance. 
Stroking Effect: a reduction in a given spastic muscle may be brought about by gently 
stroking its antagonist muscle. 
Distribution: anti-gravity muscles are differentially more affected by spasticity 
Rigidity: the increased muscle tone is not velocity-dependent and remains throughout the 
range of its movement. 
Gegenhalten (“counter hold”): it is an increase in muscle tone proportional to the force 
applied to move it passively, and may be falsely mistaken for the patient‟s own active effort. 
23 
 
Catatonia: this increase in muscle tone results in patients maintaining limbs in positions 
placed by others for a long time.  It is often associated with a wide range of psychiatric, 
neurological and medical conditions, accompanied by abnormal behavioural, affective and 
autonomic features. 
FACTORS AGGRAVATING SPASTICITY 
The history and physical examination should rule out the following factors that may be 
aggravating the spasticity and interfering with rehabilitative efforts to alleviate the same: 
Injuries and untreated fractures 
Urinary Tract Infection, Renal or Cystic calculi 
Constipation 
Pressure Ulcers 
In-grown toenails 
Deep Vein Thrombosis 
Ill-fitting Orthotics or clothing 
Improper seating 
Post-traumatic syringomyelia 
Patients and/or their care-givers must be educated in regularly monitoring for these factors 
that need immediate attention for reducing spasticity and the complications that arise from it. 
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MEASURING SPASTICITY 
In order to effectively plan interventions for managing spasticity, it must be measured and 
documented by the right instruments.  The degree of spasticity may vary with ambient 
temperature, fatigue, time of the day, posture and positioning of a limb. While there are 
several scales by which it may be measured, some are more subjective, others require more 
technical training to administer and no one scale is clinically acceptable universally. The 
various tools for measuring spasticity can be broadly classified as follows (30) : 
Measures of Increased Tone 
 Modified Ashworth Scale 
 Tardieu Scale: The Tardieu 
 Pendulum Test 
 Tone Assessment Scale  
Among the scales used to measure tone, clinically the most commonly used ones are 
the Modified Ashworth Scale (MAS) and the Tardieu Scale, both of which are 
described in more detail, as follows:  
THE ASHWORTH SCALE 
Score Ashworth (Ashworth 1964) 
0 No increase in tone 
1 Slight increase in tone giving a catch when the limb is 
moved in flexion/extension 
2 More marked increase in tone through most of the ROM, 
but limb is easily moved 
3 Considerable increase in tone – passive movement is 
difficult, ROM Is decreased 
4 Limb rigid in flexion and extension 
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THE MODIFIED ASHWORTH SCALE 
Score Modified Ashworth 
(Bohannon & Smith, 1987) 
0 No increase in tone 
1 Slight increase in tone giving a catch, release and minimal 
resistance at the end of range of motion (ROM) when the 
limb is moved in flexion/extension 
1+ Slight increase in tone giving a catch, release and minimal 
resistance throughout the remainder (less than half) of ROM 
2 More marked increase in tone through most of the ROM, 
but limb is easily moved 
3 Considerable increase in tone – passive movement is 
difficult, ROM is decreased 
4 Limb rigid in flexion and extension 
 
 
The Tardieu Scale 
Score Description 
0 No resistance throughout the course of the passive movement 
1 Slight resistance throughout the course of passive movement, 
no clear 
catch at a precise angle 
2 Clear catch at a precise angle, interrupting the passive 
movement, followed 
by release 
 
3  Fatigable clonus with less than 10 seconds when maintaining 
the pressure 
and appearing at the precise angle 
4 Unfatigable clonus with more than 10 seconds when 
maintaining the 
pressure and appearing at a precise angle 
 
5 Joint is immovable 
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The Tardieu Scale 
Score Velocity Description 
V1 As slow as possible, slower than the natural drop of the limb 
segment under 
Gravity 
 
V2 Speed of limb segment falling under gravity 
V3 As fast as possible, faster than the rate of the natural drop of 
the limb segment 
under gravity 
 
The Tardieu test is performed with patient lying in the supine position, with the head in 
midline. Measurements are taken at 3 velocities, namely V1, V2, and V3. Responses are 
recorded at eachvelocity as X/Y, with X indicating the 0 to 5 rating, and Y indicating the 
degree of angle atwhich the muscle reaction occurs.On moving the limb at different 
velocities, the response tostretch can be more easily graded since the stretch reflex response 
to velocity can vary. 
 
Measures of focal spasticity 
- Leeds arm spasticity impact scale 
Neurophysiological Measures 
 H-Reflex 
 F-Waves 
 H-max/M-max Ratio 
 Vibration Inhibition Index (H-Vibration/H-Control) 
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Patient Reported Scales 
 Visual Analogue Scale 
 Penn Spasm Frequency Scale (PSFS) 
 Patient Reported Impact of Spasticity Measure (PRISM) 
 
Functional Assessment Scales 
 Dynamic Gait Index 
 6 Minute Walk Test 
 10 Metre Walk Test 
 Timed Get Up And Go (TUG) Test 
The Modified Ashworth Scale requires no instruments, can be administered easily and is 
hence the most frequently used clinical measure.  Although it is an ordinal scale, it has the 
following limitations(31):  
*It has poor inter-rater reliability, as the passive force applied by examiners can vary 
*The six-level ordinal scale is not sensitive to change 
*Soft-tissue contractures cannot be differentiated from spasticity by this scale  
It is for this reason that we opted to simultaneously use neurophysiological measures such as 
the H-Wave, M-wave and a ratio of their amplitudes as a measure of spasticity. 
 
  
28 
 
THE H-REFLEX, M-WAVE AND H/M RATIO 
Introduction:  
The H-reflex was named after Paul Hoffman who originally described it in 1910. It is an 
electrically induced reflex that is analogous to the spinal stretch reflex, with the difference 
being the bypassing of the muscle spindle and hence, it is a valuable tool in assessing alpha 
motoneuron excitability when presynaptic inhibition and intrinsic excitability are constant. 
The H-Reflex may be used to assess the nervous system‟s response to various neurologic 
conditions, musculoskeletal injuries, therapeutic modalities, pain, exercise regimens and in 
performance assessments.(32) 
Eliciting the H-Reflex Pathway & Representation of H-Max: 
To elicit the H-Reflex, a percutaneous electric stimulus is applied to a mixed nerve, 
beginning with a low-intensity stimulus until depolarization of the primary (Ia) afferents from 
the muscle spindle. The muscle spindle itself is bypassed and activation of Ia fibres arising 
from it results in action potentials being propagated towards the spinal cord. With sufficient 
depolarization, neurotransmitters are released from the presynaptic terminal into the Ia-alpha 
motoneuron synapse, eliciting excitatory postsynaptic potentials (EPSPs). Depending on the 
alpha motoneuron membrane potential and the size of the EPSPs, action potentials are 
generated, causing Acetyl Choline release at the NM junction, contraction of muscle and 
appearance of an H-Reflex tracing on the EMG. At low levels of stimulation, the afferent 
fibers are preferentially stimulated due to their intrinsic properties and large diameter. More 
Ia afferent fibers get recruited as the stimulus intensity increases, resulting in activation of 
more motoneurons and amplitude of the H-reflex.  
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The length of the H-Reflex pathway depends on the distance of a given muscle from the 
spinal cord. Action potentials must travel up the afferent fibers to the motoneurons and then 
down the motor axons to the muscle. The time taken for the H-Reflex to appear on the EMG 
relative to the introduction of the stimulus and is known as its Latency. While the soleus H-
Reflex has a latency of around 30 milliseconds, the vastus medialis appears approximately 
15milliseconds after stimulus delivery. 
Eliciting the M-Wave Pathway & Representation of M-Max: 
 The threshold of a motor axon is higher and hence the stimulus required to activate these 
fibres is much higher than that required for Ia sensory neurons. The larger the axon, the easier 
it is to stimulate the neuron, and it is possible to preferentially stimulate the Ia sensory 
neurons before the motor axons are activated. When the intensity of a stimulus reaches 
depolarization threshold for the efferent fibers, action potentials are generated towards the 
neuromuscular junction, causing the muscle to contract. As this impulse did not pass through 
the spinal cord, it is not referred to as a reflex but termed the M-wave. Relative to the H-
reflex, the M-wave has a short path to travel before a muscle response occurs and hence its 
tracing appear on the EMG at a shorter latency of approximately 6 to 9 milliseconds.  
 
The Recruitment Curve: 
The tracings for both Ia afferent and alpha motoneuron fibres present simultaneously once the 
threshold for each one is reached. The H-reflex tracing begins to appear on the EMG at low 
levels of stimulation and as the stimulus intensity increases,depolarization threshold for the 
M-wave is achieved. As the stimulus intensity is increased, the H-reflex reaches its maximum 
amplitude (H-max). Simultaneously, the M-wave tracing begins to appear on the EMG; 
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however when stimulus intensity exceeds that required to elicit an H-max, the H-reflex 
amplitude begins to decrease and the M-wave continues to increase in amplitude. Eventually 
the H-reflex disappears while the M-wave amplitude reaches its maximum value (M-max) 
and then continues to plateau, regardless of the strength of the stimulus. (Fig. 1) 
Figure 5. The H reflex and M wave recruitment curve 
 
*The blue line in the graph above represents the H-Reflex amplitudes while the red line 
represents the amplitudes of the M-wave. 
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The disappearance of the H-reflex is explained by an effect known as antidromic collision. 
Antidromic impulses are a volley of electric activity travelling the non-physiological 
direction in the motor axons. As it travels backward up the motor axon towards the spinal 
cord, it collides with the reflexive orthodromic (impulse going in the correct direction) 
volley, which had proceeded up the sensory axon and passed through the spinal cord. When 
the antidromic volley is smaller than the afferent volley, the afferent volley is reduced but 
continues to the muscle. This explains the decrease in the H-reflex amplitude after reaching a 
maximum in the recruitment curve tracing. As the size of the antidromic volley exceeds the 
afferent volley, no signal proceeds to the muscle and the H-reflex disappears from the tracing.  
Figure 6. Tracing of H-reflex and M waves 
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What H-max and M-max Represent: 
H-max is an estimate of the maximum number of motoneurons that are capable of being 
activated in a given state. M-max represents activation of the entire motoneuron pool and 
once it is reached, every motoneuron that supplies the muscle of interest is thought to be 
activated. 
The H-max/M-max Ratio: 
H-Reflex normalization is commonly done by standardizing the H-max amplitude to the M-
max amplitude. H-max is only an indirect estimate of the number of motoneurons being 
recruited while M-max represents the entire motoneuron pool. The H-max/M-max ratio may 
be interpreted as the proportion of the entire motoneuron pool capable of being recruited and 
based on the assumption that the M-wave amplitude is a stable value. As the stimulating or 
recording electrodes are prone to move, one cannot assume that the same portion of the 
motoneuron pool is being stimulated. Hence the H-max/M-max ratio is a dependent measure 
when data are being collected on multiple occasions and it is preferred over the H-reflex as a 
percentage of the M-wave. 
 
MANAGEMENT OF SPASTICITY 
Effective treatment must begin with setting treatment goals which are in agreement with the 
patient and the therapy team, meaningful and easily understandable for the patient. They may 
include facilitation of better standing, walking and sitting, performance of activities of daily 
living, relief of pain & discomfort, reduce the burden on care-givers, prevention of 
complications such as contractures, heterotopic ossification and pressure ulcers.  
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Once the triggers for spasticity mentioned earlier have been identified and eliminated, non-
pharmacological interventions and medications can be initiated. 
Positioning of the patient also plays an important role in preventing the development of 
abnormal posture while sitting and lying down. Therapeutic positioning of the patient is 
aimed at the manipulation of primitive reflexes such as labyrinthine and tonic neck reflexes, 
released from higher motor control.  
Physical modalities, electrical stimulation may also be attempted and they have the advantage 
of not causing the drowsiness induced by many anti-spastic drugs. Intractable cases not 
responding to the above methods will require surgical intervention.  
 
NON-PHARMACOLOGICAL INTERVENTIONS 
PASSIVE STRETCHING  
The excitability of motor neurons and the visco-elasticity of muscles and joints can be 
decreased by passive stretching. (33) Stretching exercises delivered by therapists or carers are 
time and labour intensive and the duration of stretch may vary along with the intensity of 
force applied and the repetitions delivered per session.  
Stretching is defined as the process of producing elongation.  It is used commonly to deal 
with numerous other impairments including range of motion limitations and functional 
mobility. Stretching can be administered by manual techniques along with other therapeutic 
interventions; however, this makes its efficacy difficult to scientifically measure, standardize 
and objectify. Stretching can also be administered by mechanical devices like the 
dynamometer (Cybex).  
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The application of stretch is described by therapists in terms of: 
a) Duration: period of time that the stretched structures are elongated within one 
repetition. 
b) Dose: it is the total end range time. 
c) Frequency: is used to describe the periodicity ranging from one session to daily 
sessions over weeks, months or in some instances, years. 
d) Repetitions: refer to the times a muscle or joint is stretched in a single session. 
Time constraints and cost-effectiveness have fuelled the search to find alternative devices 
to apply stretch. The use of tilt tables has helped in the management of limitations in joint 
range of movement; minimize sequelae of spasticity and deficits in the lower limb range 
of movement, particularly in the gastrocsoleus muscle. Increasing the verticality and 
making the patient stand more upright causes increased weight-bearing load on the feet 
and in turn brings about a range of other benefits. If tolerated, the patient then graduates 
to a standing frame, providing static stretch to the plantar flexors of the ankle and to hip 
flexors.  Dynamometers include Cybex, Kin-Com, and Biodex where intelligent feed-
back-controlled devices are being used by clinicians to provide well regulated 
standardized stretch therapy.  
SERIAL CASTING 
Serial casting, also known as inhibitory casting has been utilized in the management of 
spasticity for decades, being first described in the 1960s when it was applied in children with 
cerebral palsy. Contractures are a leading complication in spasticity due to the prolonged 
period in which muscles remain shortened in this condition. In most cases, this complication 
is identified too late and casting is not as productive once contractures have set in completely. 
Serial casting involves the stepwise circumferential application of fibreglass or plaster of 
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Paris cast around a joint or multiple joints that are spastic and/or contracted. Repeated 
application reaps benefits in terms of better range of movement, function and decrease in 
pain. This repeated procedure may be stopped once maximum range of movement at a given 
joint is attained or 2 sequential casts do not yield any further improvement in the range of 
movement. Subsequently, the final cast in bivalved to serve as maintenance orthosis.  
Numerous theories have been suggested to explain the benefits of serial casting. A 
neurophysiological theory suggests the ability to minimize change in muscle length, in turn 
reducing excitatory input via afferent receptors in the muscle spindles, thus reducing 
reflexive alpha motor neuron excitability. Raised levels of tension within spastic muscles also 
result in increased activation of golgi tendon organs which inhibit alpha motoneurons through 
type Ib afferent fibers. The neutral warmth generated within a cast is an alternative theory 
stated, wherein motor neuron excitability is inhibited by the warmth and muscle relaxation is 
prompted. A mechanical explanation has also been suggested, where the cast provides a 
stretch of load for a long duration, helping to prevent and correct joint contractures. Animal 
studies have demonstrated the alteration in muscle and tendon properties, showing an 
increase in sarcomeres in series, as a response to casting. 
Casts or splints with or without prior botulinum toxin injections can keep joints stretched for 
hours or days and even treat contractures.  Although a recent study showed no significant 
benefit with stretching in neurological conditions(34), there has been no evidence to show 
that it may be harmful.  
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DYNAMIC SPLINTING 
Splints may be dynamic or static in nature. The goal of dynamic splints is to avoid 
immobilization while still achieving chronic stretch.  Static Splints have the advantage over 
casts in that they can be easily removed, allowing for monitoring of current range of motion, 
vascular condition and skin changes, and scheduling time windows reserved for passive and 
active movements.Dynamic splinting consists of devices incorporating active, passive 
component or active assistance into a device used to maintain stretch of muscle. Commonly 
used dynamic splints include dynasplint, Saeboflex and other custom fabricated devices often 
incorporating a system of springs and pulley systems to facilitate the dynamic component of 
the splint. 
SAEBOFLEX 
The Saebo splints include the Saeboflex, the Saeboreach and the Saebostretch with each 
providing specific effects at specific joints. The Saeboflexorthosis allowed for rapid training 
of grasp and release functions in hemiplegic hands where limited extension is caused due to 
flexor hypertonicity.  While Saeboflex training has also been incorporated as a component of 
constraint induced movement therapy, currently its applications have been mainly studied in 
the hands and remain to utilized further in lower limb spasticity management. 
DYNASPLINTS 
These devices are composed of cushioned adjustable cuffs with struts placed medially and 
laterally, acting as hinges at the joint axis. This allows for greater amounts of stretch coupled 
with an increase in duration of time that the splint is worn and in turn progressively improves 
the range of movement. Wearing time progresses rapidly when the risk of skin breakdown is 
limited and the patient is not in any form of discomfort. Numerous studies have been 
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conducted on the efficacy of this modality in improving spasticity, some in combination with 
other therapeutic interventions such as botulinum toxin injections. Most studies have shown 
an improvement in the joint range of movement while significant decrease in spasticity was 
not observed. 
 
LYCRA GARMENTS 
These are garments made in segments that are stretched in the desired orientation and 
accordingly sewn together to facilitate a particular direction of pull. They were designed to 
worn for several hours each day, producing prolonged stretch of spastic muscles. The 
elasticity of the material can be harnessed to exert direction to the continuous stretch of 
targeted segments. Thus far limited evidence is available on whether these garments are 
capable of improving spasticity significantly. They require custom-fitting and it may not be 
economical for mass-production. Patients tend to experience heat and discomfort in areas 
covered by these garments and this has also been an impediment in their role in spasticity 
management.  
 
ANKLE FOOT ORTHOSES 
The ankle foot orthoses (AFO) has been found to be beneficial in reducing plantar flexor tone 
and for positive support reaction while walking.(41) The most common ankle foot orthosis 
prescriptions are those for foot drop, plantar spasticity and lumbar spinal cord injury.  For 
plantar spasticity frequently associated with cerebrovascular accidents, either a hinged 
custom plastic AFO with a single midline posterior stop or a hinged custom plastic AFO with 
pins incorporated within the posterior channels to ensure plantar stop at 90 degrees. The 
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former is to be considered in milder cases of spasticity where a significant inversion 
deformity is not present. The latter is used when a significant inversion deformity is 
associated with the equinus foot and the common medical measures to address this spasticity 
have been exhausted.  Posterior pins within metal ankle joints would provide better 
mediolateral support while permitting some dorsiflexion, leaving the anterior channels open. 
Allowing the foot to dorsiflex can in turn provide a therapeutic stretch with a more 
normalized gait pattern, stretching the plantar flexors from the midstance to toe-off phases of 
the gait cycle.  
 
EXERCISES 
They consist of manual stretching of muscles shortened by spasticity, with brief high load 
periods for a few minutes (High-Load Brief Stretch {HLBS}). While mechanical devices can 
be used to deliver cyclic passive stretching that increases the resting length of muscles(35), 
self-stretching might be used based on the patient‟s physical and cognitive abilities, 
motivation and understanding of instructions received from a therapist. The latter could have 
potentially have advantages in terms of longer duration of daily stretch per muscle 
(depending on patient self-discipline), cost-effective in sparing therapist time, and increased 
limb awareness & decreased disuse.(36) Two therapeutic exercise approaches have been 
described in dealing with spasticity, namely the Bobath(37) and Brunnstrom(38). The Bobath 
strategy advocates reduction of primitive postural reflexes followed by facilitation of 
voluntary activity in paretic muscles through controlled stretching of muscles and attention to 
trunk posture. The Brunnstrom strategy focuses on the stimulation of the weak agonist 
muscle groups to bring about Ia mediated reciprocal inhibition of the spastic antagonist 
muscles. Heat and cold therapy can concurrently provide sensory stimuli, resulting in a short-
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duration reduction in spasticity.(39) Contrary to previous belief, exercises do not worsen 
spasticity and those studied to be beneficial include cycling, strengthening exercises and 
treadmill-based training.(40) Exercise may be deferred if patient has osteoporosis, 
coagulation disorders or severe limitation of passive range of movement. 
Unloaded cycling was studied to evaluate the effects on spasticity. Research done on this 
modality has been mainly among patients with multiple sclerosis. It has shown to have a 
positive effect on spasticity contrary to earlier opinion that it was bringing about a worsening 
of hypertonia.  
Body weight-supported ambulation has been suggested as a means of improving levels of 
mobility after a stroke. Details of this modality have been discussed further in another section 
on newer therapeutic modalities in the management of spasticity 
Numerous randomised controlled trials have been conducted, examining the benefits of 
strength training in patients undergoing rehabilitation in poststroke hemiplegia. While no 
specific improvements in spasticity were observed with high-intensity strength training, 
progressive resistive training has been shown to have a positive effect on over-all functional 
ability. In the lower limbs specifically, studies have shown that resistance training produced 
improvements in gait speed and strength but no increase in spasticity. Further study is 
required to dispel or support the opinions on whether or not resistance training worsens 
spasticity.  
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DRUG TREATMENT OF SPASTICITY 
ORAL DRUGS 
BENZODIAZEPINES 
Benzodiazepines such as Diazepam facilitate pre-synaptic inhibition in the spinal cord by 
enhancing the post-synaptic effects of Gamma Aminobutyric Acid (GABA) in the spinal 
cord. They interact with an allosteric protein modulator of GABA-recognition sites and thus 
increase the receptors‟ affinity for GABA. This in turn promotes efficient chloride 
conductance across the nerve membrane – a mediating mechanism for both presynaptic and 
postsynaptic inhibition. The indirect GABA-mimetic action of Benzodiazepines is exerted 
only when physiological GABA transmission already occurs – they merely fine tune release 
of the neurotransmitter at a synapse.(42) 
Patients begin treatment with 2mg tablets, twice a day and the dose may be slowly increased 
by a tablet every 3-4 days until a maximum dose of 10mg thrice daily is achieved. 
Benzodiazepines are useful to treat spasticity that disturbs sleep – nocturnal spasms respond 
well to treatment with Clonazepam. Side effects of this category of drugs include marked 
sedation, cognitive dysfunction (24) and behavioural changes. Diazepam may potentiate the 
hypotensive action of anti-hypertensive drugs and diuretics. Sudden withdrawal, especially 
after long-term use or in patients addicted to alcohol can cause seizures or other fatal 
symptoms.  
GABAPENTIN 
This drug in an analogue of Gamma amino butyric acid (GABA), however its mechanism of 
action is still not clear. Although it is not known to mediate its effects through interaction 
with GABA, that view has now been altered. The current prevailing view is that regardless of 
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the precise mechanism of action, Gabapentin does increase GABA turnover. It is also used in 
the adjunctive treatment of seizures and also has been used in the management of neuropathic 
pain.The most frequently noted side effects of Gabapentin are somnolence, vertigo, 
nystagmus, headache, tremors, fatigue, ataxia and nausea. 
 
BACLOFEN 
This widely used anti-spastic drug is a derivative of GABA and acts specifically as an agonist 
of GABA-B receptors. It also acts by reducing calcium influx and suppressing the release of 
excitatory neurotransmitters such as aspartate and glutamate. It is effective in the initial 
management of spasticity, with a starting dose of 5mg thrice daily, increments of 5-10mg can 
be made weekly till an optimum effect is achieved. Maximum doses ranging between 100-
120mg per day may be well tolerated.  Special attention must be paid while adding other 
classes of medicines such as tricyclic antidepressants and Baclofen must be tapered rather 
than stopped abruptly in patients with seizures as it reduces the seizure threshold. Sudden 
withdrawal can also provoke rebound spasticity and hallucinations. Side-effects of this drug 
include weakness, dizziness and drowsiness.(43) 
 
CLONIDINE 
Monoamines are distributed throughout the central nervous system and in spastic hypertonia; 
they modulate sensory, autonomic and motor functions by facilitating pre-synaptic inhibition 
of spinal afferent impulses. In this manner, monoamines have an important role in 
modulating spinal neuron excitability.  
42 
 
Clonidine was one of the initial centrally acting alpha-2 and imidazoline type-I adrenergic 
receptor agonists to be used in spasticity. It also serves as an alpha-1 central adrenergic 
agonist. This was realized by its potential as an anti-hypertensive medicine, antagonized by 
Yohimbine.  In spasticity, it modulates pre-synaptic inhibition of sensory afferents via alpha-
2 adrenergic receptor effects. It is a highly lipophilic medication with consistent distribution 
regardless of whether it is delivered via oral, transdermal, intravenous, epidural or rectal 
routes.  
 
CYPROHEPTADINE 
While the mechanisms through which serotonin exerts its effects on spastic hypertonia are 
not clearly known, serotonin blockers such as cyproheptadine have been studied and utilized 
in its management. It has also been used to manage symptoms of serotonin syndrome 
associated with baclofen withdrawal and has been approved for the treatment of headaches, 
anorexia and hives. Cyproheptadine may alleviate the effects of intrathecal baclofen 
withdrawal, indicating that GABA-B receptors inhibit the release of serotonin and also 
supports its role in movement disorders. The most prominent side-effects associated with 
Cyproheptadine are somnolence and weight gain. 
 
TIZANIDINE 
This alpha-2 receptor agonist enhances noradrenergic in the central nervous system while 
inhibiting excitatory spinal interneurones and tracts from the locus ceruleus. Tizanidine is 
usually started at a dose of 2mg and increased by the same dose on a weekly basis. The 
maximum permissible dosage is 36mg, divided into 3-4 doses per day.   Liver enzymes must 
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be monitored periodically during the first 4 months of treatment to detect hepatitis. 
Hypotension, gastrointestinal disturbance, and a dry mouth are other possible side-effects. 
The drug must be tapered rather than stopped abruptly to avoid withdrawal symptoms such as 
tremor, tachycardia, hypertension and anxiety. 
DANTROLENE 
Dantrolene directly affects muscle contractile mechanisms, specifically on extrafusal fibres 
and not on the intrafusal fibres involved in reflex pathways. It blocks calcium release from 
the sarcoplasmic reticulum and interferes with excitation-contraction coupling in the skeletal 
muscle. As it acts directly on the muscle, it has less central nervous system side-effects like 
sedation. Beginning with a dose of 25mg daily over the first week, increments of 25mg can 
be made to a top dose of 100mg, 3-4 times daily. Liver functions must be monitored regularly 
to detect the presence of hepatotoxicity. Long-term dangers of Dantrolene therapy include 
pleuropericardial reactions. 
CANNABINOIDS 
The dorsal spinal cord, basal ganglia, hippocampus and cerebellum contain cannabinoid 
receptors that can modulate spasticity. While inducing psychotropic effects, 
Tetrahydrocannabinol, a cannabinoid receptor agonist, also reduces spasticity. An 
oromucosal spray containing nabiximols, a 1:1 mixture of 9-Δ-Tetrahydrocannabino and 
cannabidiol was approved in the UK for management of spasticity in multiple sclerosis.(44) 
However, the side-effect profile including long-term effects on mental health, cognition and 
behaviour are a deterrent unless the spasticity is non-responsive to combinations of other 
anti-spastic drugs. 
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PARENTERAL DRUGS 
BOTULINUM TOXIN 
This is prepared from the Clostridium botulinium strain of bacteria which produces a 
potentially fatal neuromuscular paralytic toxin. The toxin contains a heavy chain which is 
internalised into presynaptic nerve endings where it degrades synaptosomal-associated 
protein (SNAP) 25, essential for acetylcholine vesicle fusion to the presynaptic membrane. 
Neuromuscular transmission is then blocked by inhibition of acetylcholine release into the 
synaptic cleft. The selective weakness induced in a target muscle can be reversed only a few 
months later with reinnervation and nerve sprouting. Global weakness and sedation are 
avoided with the selective reduction in spasticity of muscles injected with the toxin. Target 
muscles may be identified using electromyography, nerve stimulation or ultrasound and post-
injection interventions such as physiotherapy, splinting or serial casting must be planned to 
maximise the effects of botulinum toxin. For maximum benefit, the treating physician must 
ensure that no significant contractures exist and that all trigger factors affecting spasticity are 
addressed prior to injecting botulinum toxin. 
The duration of effect of Botulinum Toxin is around 3 months, with the causes the loss of 
effect being attributed to the formation of new neuromuscular junctions and sprouting to new 
axons proximal to the affected nerve terminal. The preparation of Botulinum toxin A (BT-A) 
available currently are Dysport and BOTOX with the latter being 3-5 times more potent than 
the other. While the advantage of using Botulinum toxin lies in the targeting of specific 
muscles, sparing of sensory fibres and patient tolerability.(45) Outcomes using this 
intervention are enhanced when used in conjunction with standard physiotherapy and 
orthoses. The disadvantages of BT are a short duration of action, unwanted weakness in 
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distant muscles by diffusion of toxin across fascial boundaries or systemic spread, and 
generalised effects such as flu-like symptoms and fatigue which are self-limiting. 
 
PHENOL NERVE BLOCK 
Phenol (Carbolic Acid) can act as a neurolytic agent in concentrations more than 3% and is 
used to impair the innervation to a spastic muscle. In the lower limb, chemodenervation of 
the posterior tibial nerve in the popliteal fossa can decrease the equinovarus deformity. 
Although the duration of its effect may range between a few months to several years, painful 
dysaesthesia occurring from damage to sensory fibres of mixed nerves is an unwanted side-
effect. Electromyography may be used to target the motor point of the target muscle‟s 
innervation, thus reducing the risk of sensory disturbance. Damage to blood vessels adjacent 
to the target nerve has also been observed, leading to vascular occlusion. Fifty percent 
alcohol may be used as an alternative to phenol, but has lesser efficacy.  
 
INTRA-THECAL BACLOFEN  
Intrathecal baclofen infusion through a pump is best applicable in refractory lower limb 
spasticity affecting patients with spinal cord injury or multiple sclerosis, where multiple 
muscle groups in both lower limbs are affected. A small study of 3 stroke patients with 
chronic lower limb spasticity, responded to continuous intrathecal baclofen infusion with 
reduced tone in the affected side and preservation of muscle power on the non-paretic side. 
(46) 
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SURGICAL INTERVENTION  
It can be divided broadly into procedures interfering with neuronal pathways and those that 
correct musculoskeletal deformity. Within the central nervous system, stereotactic 
neurosurgery and Cerebellar stimulation targeted the brain while Selective Dorsal Rhizotomy 
(SDR) targeted the spinal cord in attenuating spasticity. Stereotactic neurosurgery and 
Cerebellar stimulation have not produced satisfactory results. (47)(48) Selective Dorsal 
Rhizotomy is still being used with variable success in cases of intractable spasticity not 
responding to other modalities. (49)(50) Neurectomy has been used with some benefits in 
specific cases. However, neurectomy, particularly of mixed motor and sensory nerves, can 
have unfortunate consequences leading to permanent painful dysesthetic pain. Hence, the 
majority of surgical interventions for management of spasticity are performed on peripheral 
muscles and tendons to bring about significant changes in spasticity. 
The goals of surgery for spasticity are not unlike those of non-surgical procedures. While 
some focus on improving function and active movement, in others, patients have more 
advanced spasticity demonstrating limited active movement, requiring some form of passive 
functional improvement. It must be clearly explained to the patients and their care-takers that 
the goals of surgery are neither the restoration of volitional control to muscles, nor the 
increased generation of muscle power.  Other goals of surgery include pain relief, lesser 
dependence on systemic medications and their associated side effects, creating a permanent 
remedy rather than one requiring recurrent interventions, and also to improve cosmetic 
outcome and in turn the psychological well-being of the patient.  
With regard to the timing of surgical intervention, early surgery has the advantage of being 
able to work with joints which are supple and in turn the duration of disability is shorter. 
Disadvantages include neurologic conditions which may still be dynamic and unpredictable. 
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The medical morbidity associated with a recent injury to the central nervous system may also 
have consequences on an early surgical intervention. Surgical interventions at a later point in 
the management of spasticity have the advantage of the natural history of the illness taking its 
course and in turn, better healing of the initial injury. The disadvantages of a late surgical 
intervention include having to deal with stiffer joints, and the worse outcomes related to an 
already severe disability.  
The most valuable and versatile of techniques used to lengthen muscles in spasticity surgery 
is the fractional lengthening technique.  Most muscles have regions where an overlap 
between the muscle and tendon exists. It is at this level that fractional lengthening is 
performed. The region of the myotendinous junction is able to stretch where the tendon was 
cut, allowing lengthening of the structure in its entirety. The new tendon resulting from 
healing of this procedure takes about 3 months to develop and fill the ensuing gap. Care must 
be taken to prevent overstretching of the muscle during this recovery period.  
Another surgical technique commonly used is the muscle slide and advancement. In this 
procedure, the entire origin of the muscle is advanced, thus shortening the work of the muscle 
and in effect lengthening it relative to its functional movement.  Three techniques that 
lengthen a tendon include V-to-Y lengthening, Z lengthening or lengthening involving 
multiple hemitenotomies.  
Procedures specifically related to the equinus ankle spasticity utilize a lengthening technique 
and include fractional lengthening of the myotendinous junction and percutaneous 
hemitenotomies through the tendon. This involves creating a longitudinal incision over either 
the medial or lateral calf region. Identifying the interval between the gastrocneumius and 
soleus muscles, the myotendinous junctions of both muscles are demarcated and subsequently 
lengthened. Alternatively, the Achilles tendon may be approached percutaneously and 
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lengthened distally using 3 hemitenotomies. The ankle is then passively dorsiflexed, inducing 
a tear and weakening of the tendon. Hemitenotomies permit longitudinal tear of the Achilles 
tendon, leaving residual tendon fibres contiguous if appropriate healing takes place. 
Permitting weight-bearing immediately after the lengthening procedure is debatable and 
generally the ankle requires 8 to 12 weeks of protection within a cast to prevent rupture of the 
gastrosoleus muscle. Without adequate bracing and stretching following surgery, in the 
absence of any active dorsiflexion, the equinus contracture is likely to recur.  
Resection of an existing heterotopic ossification may also be required to facilitate better 
range of movement. 
 
EMERGING TECHNOLOGY IN THE MANAGEMENT OF SPASTICITY IN 
HEMIPLEGIA 
The knowledge gained from research and advancements in neuroimaging have enhanced the 
understanding of neural plasticity and the role it plays in therapeutic modalities used for the 
management of spastic hemiplegia With this knowledge, newer emerging modalities of 
therapy that are as follows: 
CONSTRAINT-INDUCED MOVEMENT THERAPY 
Constraint-induced movement therapy has emerged as an interesting therapeutic approach for 
patients with hemiplegia following a cerebrovascular accident. This intensive therapy is 
administered over the course of 12 to 15 days, restricting the use of the uninvolved limb. The 
patient is forced to use the limb on the affected side to perform activities of daily living. The 
theory of learned nonuse states that a limb weakened as a result of the cerebrovascular 
accident will not improve if it is not actively rehabilitated. Hemiplegic patients are taught not 
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to use the normal limb in the hope of developing compensatory one-handed strategies with 
the affected limb. This in turn facilitates cortical reorganisation that promotes use of the 
plegic limb.(51) Several important factors are required for constraint-induced movement 
therapy to be successful. They include intensive, repetitive practice using the affected limb 
for common functional tasks. This must be followed in conjunction with the unimpaired limb 
physically restricted for up to 90% of the time the patient is awake using a mitt, splint and/or 
sling. A therapeutic strategy known as shaping is used, which involves training of the plegic 
limb to perform successive approximation of a desired task. While traditional constrain 
induced movement therapy is extremely intensive requiring at least six hours of daily therapy 
for two weeks, the most comprehensive study examining its effectiveness to standard 
rehabilitative methods was the EXCITE trial. (52) This study included 222 patients with a 
single stroke that occurred 3to 9 months before the time of enrolment. When compared to the 
standard therapy group, those who underwent constraint-induced movement therapy had less 
self-perceptions of limb function difficulty and performed better on several tests of limb 
function. Challenges faced by the demands of intensity and time spent in constraint-induced 
movement therapy have prompted several attempts at modifying the ways it is delivered. A 
regimen providing therapy for 5 hours daily for 5 days followed by 3 hours a day, thrice 
weekly over approximately 10 additional weeks yielded results comparable to traditional 
constraint-induced movement therapy. Modifications have also incorporated online computer 
sessions or combined robotic therapy with constraint induced movement therapy.(53) Factors 
limiting the effectiveness and application of constraint induced movement therapy include the 
effort and motivation required on the part of patients receiving this therapy. Compliance with 
mitt restriction has been reported to be as low as 32%. (54) Other restricting factors include 
the baseline functions that are required in patients for this therapy to be effective and this in 
turn translates to only a small percentage of patients benefiting from this therapy. 
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VIRTUAL REALITY 
Computer-based technology has led to the development of virtual reality programs permitting 
individuals to interact within computer-generated environments simulating real-world 
settings for clinical and research applications. Technology is used to make virtual 
environments where the intensity, duration and feedback related to the therapy can be 
modified with much better control than natural environs. Therapy can be safely conducted in 
settings that would otherwise be considered too dangerous or complex in actual locations. 
Specific therapies can be administered using this technology without concerns about the 
consequences of allowing the patient to perform potentially dangerous exercises or activities 
on their own. While being extremely flexible, this technology is capable of staying 
completely consistent over infinite repetitions. Alterations in the type and pattern of sensory 
feedback and complexity of task can fulfil a range of clinical, research and assessment 
requirements. Hence virtual reality has been gaining wider applications in rehabilitation 
settings for both treatment and assessment. 
Jaffe et al developed a head-mounted device which could easily be worn like a hat while it 
displayed virtual objects and scenarios.(55) Patients wearing the device were walking on a 
treadmill while being attached to a safety-harness. Movements of the lower limb are 
promoted by negotiating virtual obstructive objects in their path. Inability to avoid a virtual 
object results in a virtual collision, resulting in appropriate feedback to the patient. With 
practice, performance was noted to improve on this virtual obstacle course and thus facilitate 
ambulation training. Fung et al devised a treadmill that could interface with a rear projector 
providing patients with auditory, visual and sensory feedback, which in turn eventually 
resulted in better velocities while walking. (56) Deutsch et al devised a seated system 
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allowing the patient to use their own ankle movement to control a foot pedal and “navigate” a 
virtual boat while receiving auditory, sensory and visual feedback. Improvements were 
observed in the endurance and velocity of gait within a month of undergoing 12 hour sessions 
on a daily basis.(57) Functional MRI has demonstrated that after training, activation in the 
contralesional hemisphere decreased while ipsilesional sensorimotor activity was 
predominant and associated with improved motor function. Similar evidence of enhanced 
activation in the affected hemisphere following the use of various virtual reality related 
therapies have shown that this modality may be useful to induce cerebral plasticity and 
improve motor skills after a cerebrovascular accident.(58) 
 
TRANSCRANIAL MAGNETIC STIMULATION 
This is a relatively new mode of therapy that is non-invasive capable of both enhancing and 
inhibiting focal brain activity, with the potential to induce cerebral plasticity and enhance 
recovery following injury. It consists of short magnetic pulses generated by the passage of a 
brief electric current through a stimulating coil, usually made of copper encased in plastic, 
and held to the surface of the scalp. Based on the pattern of pulse provided, either an increase 
or decrease in cortical excitability ensues. Unlike electrical stimulation where neurons are 
directly excited, transcranial magnetic stimulation affects neural tissue indirectly by inducing 
electrical activity via magnetism. The magnetic pulse generated depends on the spatial 
configuration of the stimulating coil with the position in which it is held.  
Transcranial magnetic stimulation can be delivered through single-pulse, paired-pulse and 
repetitive stimulation. While single-pulse stimulation over the motor cortex delves into 
information concerning corticospinal tract excitability by measuring motor response in the 
52 
 
muscles corresponding to the area of the brain that is activated, paired-pulse stimulation can 
provide information on cortical inhibition or excitation.  
Repetitive transcranial magnetic stimulation consists of a repeated train of magnetic pulses at 
either low (1 Hz) or high frequencies (5-20Hz) that can respectively cause depression or 
enhancement of cortical excitability. (59) The changes induced in excitability may last 
beyond the application of magnetic pulses implying that repetitive transcranial magnetic 
stimulation has the capacity to induce long-term potentiation conducive to cerebral plasticity. 
The changes in cortical excitability induced by transcranialmagnetic stimulation have been 
utilized to manage spasticity in several upper motor neuron conditions including stroke. Ia 
afferent sensory fibres, spinal interneurons, α and γ motoneurons are known to be modulated 
by corticospinal neurons, which in turn are involved with the generation of spasticity. 
Increasing the corticospinal tract excitability using repetitive transcranial magnetic 
stimulation is theorized to inhibit overexcitability of α and γ motoneurons, thereby reducing 
spasticity. Numerous repetitive transcranial magnetic stimulation theories have been tested 
with results demonstrating its potential to either reduce spasticity or increase passive range of 
movement. (60)(61) Functional use of affected limbs can thus be improved using this 
modality in patients with spastic hemiplegia. 
Induction of seizures is one of the primary adverse affect associated with repetitive 
transcranial magnetic stimulation which can be minimized by abiding by recommendations 
on stimulation parameters, monitoring guidelines and specifying contraindications. (61) The 
precise timing of application of transcranial magnetic stimulation to bring about maximum 
plasticity and alleviate spasticity has not yet been determined; however its effects have been 
observed at various poststroke stages. 
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ROBOT THERAPY 
Clinicians and engineers have worked in collaboration to develop numerous robotic devices 
with the intention of improving motor and functional recovery after an insult to the central 
nervous system, regardless of what the aetiology may be. This technology builds on the 
existing evidence that intense, repetitive, challenging and functionally relevant therapies are 
critical factors contributing to motor recovery. (62) Robots designed to highly repetitive and 
intense therapy are means of improving functional recovery otherwise not practically feasible 
utilizing traditional rehabilitative measures. Computer programs in robots constrain 
inaccurate limb movements to promote more functionally appropriate movements during 
specific tasks. With the intention of substituting the need for trained professionals and 
compensating for their time and labour constraints, the automated components of robotic 
therapies enhance patient compliance in interesting ways. They combine games with therapy, 
providing instant feedback on performance and thus maintain levels of motivation. Therapy 
can be guided by easily tracking changes in the skill, thus serving as a means of monitoring 
the efficacy of therapy and modifying it accordingly.  
The robotic devices developed thus far have mainly focussed on rehabilitation of hemiparetic 
upper limbs and a few prominent robotic systems that have emerged include:  
- The MIT-MANUS system 
- The Mirror Image Motion Enabler 
- The Bi-Manu Track 
- The GENTLE/s RT system 
- The Haptic-MASTER which is a part of the GENTLE/s RT system 
- The Activities of Daily Living Exercise Robot 
- The Myomo e100 
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- The Cyberglove and Rutgers Master II-ND glove 
Drawbacks of robotic therapy include the start-up costs and the dearth of validation 
from clinical trials. 
 
BODY WEIGHT-SUPPORTED TREADMILL TRAINING 
This mode of therapy was first described by Finch et al (63) with the objective of assisting 
neurologically impaired individuals with ambulation and walking.  A harness system supports 
a part of the patient‟s body weight and helps to unload the lower extremities as the patients 
train to walk on a treadmill.  Gait quality, speed and trunk stability following a stroke have 
been shown to improve with this therapy. Body weight supported treadmill training may also 
be effective in encouraging a symmetrical gait pattern, facilitating sensory feed-back and 
maximizing vital repetition required during the recovery period. 
The mechanism of action propounded for body weight-supported treadmill training is the 
activation of central pattern generators (CPGs) located in the spinal cord. Central pattern 
generators were first described in invertebrates where it was demonstrated that neuronal 
networks responded to specific sensory inputs to bring about locomotion.  
Studies have been conducted on cats in whom thoracic spinal cord lesions were induced, 
where body weight-supported treadmill training has brought about improvements in various 
aspects of gait including, speed and cadence, compared to control animals. Theories of the 
mammalian spinal cord being capable of producing reciprocal gait patterns without 
supraspinal inputs, but through the activation of central pattern generators, were thus 
supported. While there is support for the notion that neural plasticity possible within the 
spinal cord, supraspinal mechanisms may also be influenced by body weight-supported 
treadmill training. Mass practice or the need for repetition, and shaping which is the 
sequential performance of imitations of a task, can be used along with progressive weight-
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bearingto facilitate lower limb function. When administered by trained therapists, this system 
can help control leg movement, patient posture and balance that aids in mimicking the normal 
rhythmic nature of gait. Along with decrease in the fear of falling, other attributes of this 
therapy make gait training feasible earlier in a patient who has had an injury to the central 
nervous system. 
Several studies including a metanalysis have failed to demonstrate a definite advantage that 
body weight-supported treadmill training may have over traditional therapeutic techniques. 
This can be attributed to the heterogeneity in the nature and severity of stroke, differenced in 
demographic characteristics of patients, varied intensity and frequency of training, methods 
used for assistance and the placebo effect. Another important drawback has been the time 
constraints and physical demand placed on therapists to utilize this therapeutic modality to its 
maximum potential. Fatigue, not only among patients, but therapists too can limit the 
duration of a given session.  
Barbeau and Visintin (64) in their experience with body weight-supported treadmill training 
found that the transfer of training from treadmill walking speed to ground walking speed was 
better in the body weight-supported group compared to the group that trained without this 
therapy. Improvements in cardiovascular fitness have also been observed in this therapy. This 
has been attributed to the positive effect of exercise on cerebral blood flow and angiogenesis, 
facilitating information processing caused by release of dopamine and / or norepinephrine, 
improved mood and decreased depression, and finally the up-regulation of neurotropins.  
While evidence has shown some promising results, the cost of equipment, the labour-
intensive requirements, and the uncertain clinical efficacy compared traditional therapy, all 
support the need for further studies into the viability and true benefits of this therapy. 
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ELECTRICAL STIMULATION 
Electrical stimulation is a non-invasive and simple technique used extensively by 
physiotherapists, mid-wives and nurses both in the health-care and home setting.(65) It has 
been used mainly for the management of acute and chronic pain.(66)Various electrical 
stimulators have been developed for the therapeutic stimulation of tissues. Aside from pain 
management, electrical stimulation may also be used to contract or relax muscles, and to 
enhance bone growth. The stimulation is by a portable pulse generator which delivers pulsed 
currents across the intact skin surface via conducting pads called electrodes. The many 
different types of electrical stimulation can be classified as: 
- Neuromuscular stimulation (NMS) 
- Electrical muscle stimulation (EMS) 
- Functional electrical stimulation (FES) 
- Transcutaneous Electrical Nerve Stimulation (TENS) 
 
The electrical generators commonly used in clinical practice are of the following types: 
*Traditional low-voltage current generators, delivering less than 100 volts, below 1 Hz 
*High-Voltage direct current generators, with a very short-duration pulse to facilitate 
penetration in the range of 300 to 500 volts. 
*Interferential current generators, delivering between 4000 and 4100 Hz, at a net frequency 
within the interference zone ranging between 80 to 100 Hz. Its power however lies in the 
low-voltage range. 
*Trancutaneous Electrical Nerve Stimulation units, used specifically for nerve stimulation 
with frequencies ranging between 1 to 120 Hz, pulse width of 50 to 300µsec, with a medium 
range amplitude of 10 to 50 mAmps.While an increasing number of devices have been 
reported in literature, the main types of transcutaneous stimulation described at the 
57 
 
conventional type, acupuncture type and intense type. (67) The conventional type remains the 
most commonly used for delivery of current in clinical practice. (68) 
*Medium-frequency generators, designed to deliver specific frequencies ranging from 2400 
to 2500 Hz, useful especially in the management of sports injuries. 
*Subliminal generators, delivering stimuli at a non-sensory level to specific targets 
(acupuncture or trigger points) 
*Programmed units, which are tailored towards home use, with variable parameters for 
delivering stimuli and monitoring facilities 
 
TYPES OF ELECTRODES 
- Commercial pads and rubber-coated electrodes, with various mechanism of 
attachment to the skin surface 
- Moistened paper towels, with aluminium foil leads, requiring alligator clips for 
connection to the leads 
- Sponge pads with rubber carriers and electrodes inserted within. 
- Carbonized rubber electrodes  used in (TENS) which require gel for transmission of 
stimuli 
- Copper-tipped electrodes used for internal administration (intra-vaginal) 
ELECTRODE DIMENSIONS: 
Treatment technique and current configuration determine electrode sizes which can be varied: 
- Equal sizes: they ensure equal distribution of current 
- Differential sizes: for shaping of current 
- Special instruments for internal administration of current 
  
58 
 
ELECTRODE TIPS 
- Alligator Tip: for connecting aluminium plate electrodes 
- Banana Tip: for standard receptors 
- Telephone Tip: for pin-shaped receptors 
- Snap Tip: for button-type connections 
 
SECURING DEVICES  
These devices are required to inhibit movement of electrodes during the administration of 
electrical stimuli. They have to be composed of an insulating material to prevent conduction 
of electrical stimuli across their surfaces. They are: 
- Soft-rubber sandbags 
- Lightweight sandbags 
- Adhesive gels 
- Velcro bands 
- Adhesive tapes 
 
TYPES OF CURRENT: 
- Alternating Current: This offers alternating polarity upon recurrent altering between 
positive and negative numerous times per second. Sine waves are generated when the 
alternating phases are equal in energy and smooth. It generates a comfortable 
waveform, usually used for application to neuromuscular components with no 
reaction of degeneration (RD) 
 
- Direct or Galvanic current which represents a constant flow of electrons from the 
negative to the positive electrode without any alterations (constant polarity) 
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- Continuous direct current is one which is used only for iontophoresis. 
 
- Interrupted (pulsed) direct current was used in the past for stimulation of 
neuromuscular components with RD, as their ability to respond to alternating current 
has been lost. However it seldom used now in view of its adverse effects on muscle 
fibers being stimulated. 
 
 
- Surged direct current which is also rarely used nowadays because of its slow wave 
rise, leading to tissue accommodation, which in turn causes minimal or no contraction 
 
- Faradic current can safely used with neuromuscular tissues without any RD. 
Resembling alternating current in most traits, it tends to cause more irritation 
 
 
- Interferential current is unique in that it results from the combination of two high-
frequency waveforms (4000 and 4100 Hz) in a crossed pattern.  This net frequency 
which results from the cancellation or reinforcement phenomena near or at the 
crossing point roughly equals a 100 Hz. Its penetrating quality is attributed to higher 
frequencies and a shorter pulse width to reach deeper tissues. Unless high amplitudes 
are used, this current does not produce visible contractions. 
 
- High Voltage-pulsed Galvanic Current: To be effective in improving muscle strength, 
electrical stimulation should be capable of producing strong muscular contraction 
with a low pain response. To produce such an effect, the electric pulse should be have 
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an altered waveform, duration, frequency and intensity to minimize pain and 
discomfort. Slow rising pulses minimize pain while high voltage-pulsed galvanic 
current (HVPC) with its short duration and deep penetration provide effective stimuli 
to strengthen muscle. High voltage generators produce upto 500 volts, with a short 
duration (lesser than 100msec), a high peak (up to 2 amperes) with a low average 
current (less than 150mAmps). The waveform consists of a twin-peaked pulse, spaced 
40-80msecs apart. 
 
 
Three major modes can be used to administer the above mentioned forms of current: 
- Continuous Mode: When rate or frequency of stimulus exceeds 50Hz, it is more 
useful for relaxation of muscle spasm 
- Surged Mode: this mode is used to attain maximum current intensity within 
microseconds to milliseconds. Slow surges (5 to 10 in a minute) stimulate slow 
muscle fibres better. 
- Interrupted or Pulsed Mode: with sharp interruptions, alternating current can reach 
peak intensity immediately, leading to a brisk muscle response, being suitable for fast 
muscle fibre stimulation. Pulses exceeding frequencies of 50 Hz cause titanic 
contraction. 
 
WAVEFORMS 
- Sine wave: offer equal energy levels in both the positive and negative phases 
- Rectangular Wave: This wave usually describes direct current with a sudden rise, 
followed by a prolonged duration and a sharp drop-off. 
- Spike Wave: this waveform is characterised by a rapid rise rate which is not sudden, 
then falling rapidly back to zero immediately after attaining maximum amplitude. 
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- Combined waves: this wave resembles a combination of both the rectangular and 
spike waveforms. 
- Twin-spiked Forms: this waveform achieves greater penetration of the stimulus 
applying an extremely short pulse width, as in high voltage galvanic stimulation. 
 
PARAMETERS OF ELECTRICAL STIMULATION 
 FREQUENCY (Pulse Rate): Frequencies ranging between 80 to 120 Hz are 
recommended for acute conditions of pain. The resulting tetanising rate produces 
smooth contraction, which in turn causes relaxation of muscle spasm. Contrarily, 
low frequencies of 1to 20 Hz are recommended for chronic conditions to stimulate 
endorphin production and analgesia. 
 
 DURATION (PULSE WIDTH): With most equipment available today, pulse 
width ranges between 50 and 500 msec. While a medium width of 150 msec is 
preferred most, increases in pulse width cause an apparent increase in strength of 
the stimulating current as it is in the “on” phase for a longer period. 
 
 AMPLITUDE (INTENSITY):When subjecting a muscle to electrical stimulation, 
a visible contraction as tolerated by the patient is recommended as a guide for 
setting the intensity of stimulation. In interferential current however, the effects 
are too deep and localized for the therapist to see or feel. Being cautious in 
patients with impaired sensory function, patient response can be a guide for 
regulating the intensity of the electrical stimulus.  
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 MODULATION: current is modulated with the long-term application of TENS 
for pain management. Modulation of frequency, duration or amplitude can be 
done with the goal of reducing accommodation or the body‟s adaptation to the 
electrical current stimulus. 
 
 BURST PHENOMENON: The burst mode is beneficial for muscle stimulation as 
it resembles the interrupted mode and may also be used in TENS. 
 
 Conventionally, the stimulation is administered using electrical characteristics which 
selectively activate large diameter (Aβ) „touch‟ fibres, avoiding smaller diameter (Aδ and C) 
nociceptive fibres. This delivers a strong but comfortable paraesthesia at the site of 
administration, using frequencies ranging between 1-250 pulses per second (p.p.s) and pulse 
durations between 50-1000 µs. Electrical stimulation has few side-effects or drug interactions 
and no potential for toxicity or overdose, and patients may themselves titrate the dosage as 
required. In these ways, it is more cost-effective when compared with long-term drug 
therapy. 
 
 HISTORY OF ELECTRICAL STIMULATION 
Evidence of transcutaneous electrical stimulation exists from time of ancient Egyptian 
civilization which used electrogenic to treat ailments in 2500BC. The Roman physician 
ScriboniusLargus first documented a report of the use of electrogenic fish in AD46(69)The 
eighteenth century saw the development of electrostatic generators which were increasingly 
used by physicians, but declined in popularity due to variable clinical results and other 
available  therapeutic measures. In 1965 Melzack & Wall provided the physiological 
63 
 
rationale for relieving pain with electricity. They proposed that pain-inhibitory pathways 
descending from the brain and activity in large diameter peripheral afferent nerves can be 
harnessed to block transmission of noxious information to the brain.    
 
PHYSICAL PRINCIPLES 
The standard device delivering transcutaneous electrical stimulation target large diameter 
nerve fibres such as Aβ and Aα which have low thresholds of activation, when compared to 
small diameter Aδ and C fibres. The current amplitude required to excite a nerve fibre 
declines with an increase in pulse duration and frequency. Selective activation of large 
diameter (Aβ) fibres without activation of small diameter Aδ and C fibres can hence be 
achieved with low-intensity, high-frequency (10-250Hz) currents with pulse duration 
between 10 and 1000 µs.(70) 
As the impedance of intact skin and underlying tissue is complex and non-homogenous, it is 
difficult to exactly predict the distribution of current passing through it. With the pulse 
frequencies used in conventional transcutaneous electrical stimulation, the current is likely to 
remain superficial, stimulating cutaneous nerve fibres rather than deep-seated visceral and 
muscle nerve fibres. The pulse waveforms available in devices can be divided into 
monophasic and biphasic waveforms. (FIG 17.5) The cathode which is usually identified 
using a black lead excites the axon and in practice, it is placed proximal to the anode to 
prevent the hyperpolarisation that could block nerve transmission. (Fig 17.6) Devices using 
biphasic waveforms alternate the cathode and anode between the two electrodes, resulting in 
zero net current flow. This prevents the build-up or polar concentration of ions that could 
cause adverse skin reactions.(70) 
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MECHANISM OF ACTION 
Spasticity and motor dysfunction in upper motor neuron lesions result from a combination of 
lack of descending supraspinal control and a decrease in presynaptic inhibitory mechanisms 
acting on muscle spindle afferent terminals.(71)Low threshold afferent input has been shown 
to reduce ongoing activity in alpha motoneurons and or interneurons via segmental, 
supraspinal or propriospinal pathways.(72)Speculation has also attributed the release of 
inhibitory neuromodulators for the effects of electrical stimulation on pain 
management.(73)Previous studies have shown electrical stimulation to produce significant 
prolongation of H and stretch reflex latencies in calf muscle spasticity, lasting up to 60 
minutes following the stimulation.(74) 
As spasticity was partly related to enhance stretch reflex excitability(75), Levin & Chan 
repeated electrical stimulation over a period of weeks (15 days of 60 minute sessions) to 
observe the effects on hyperactive stretch reflexes, subjective spasticity and maximal 
voluntary isometric ankle contractions among hemiparetic subjects. They were compared 
against placebo stimulation applied to a similar group for the same period and found to be 
beneficial.Repetitive electrical stimulation is speculated to have improved dorsiflexor 
function by increasing presynaptic inhibition, reducing hyperexcitability of the soleus stretch 
reflex, and reducing the EMG co-contraction ratio. These changes could have been mediated 
by plastic mechanisms such as sprouting of intact descending pathways, making new 
synapses with motoneurons or re-organizing somatosensory-motor cortical connections.(76) 
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PRINCIPLES FOR APPLICATION OF ELECTRICAL STIMULATION 
ELECTRODE POSITION 
Electrodes should always be applied to healthy innervated skin. In the case of pain 
management, they are placed either at the site of pain, proximal to the site of pain over the 
main nerve trunk innervating that area or over the spinal cord at segments associated with the 
origin of pain. In cases of spasticity management, electrodes have been placed over the target 
muscles, nerves supplying the muscles wherever they are sufficiently superficial and 
accessible, and over the appropriate segments of the spinal cord responsible for innervating of 
the target muscle.  
PREPARATION OF THE PATIENT: 
- The skin where electrodes will be placed must be cleaned thoroughly 
- Special gels, sprays or water may be applied to the skin as medium to facilitate 
stimulation 
- Electrodes are fixed in position using mending tapes ensuring good contact 
throughout the period of stimulation. Adhesive electrodes are also available and were 
used for stimulation by therapists in this study. 
 
ELECTRODE PLACEMENT 
Electrode placement is determined by the target nerve, muscle or muscle group. 
Placement alternatives recommended are:  
- Unilateral: This type of electrode placement is used for stimulation of a limb or one 
half of a muscle pair. 
- Bilateral: This type of stimulation can be used to target both limbs or, both halves of a 
muscle pair. 
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- Unipolar: In this technique the motor point is stimulated with the active electrode 
placed over the target muscle, while the indifferent electrode is placed elsewhere. 
- Bipolar: In this technique, two electrodes are used to target the muscle, close to the 
origin or the insertion. 
- Bilateral unipolar: In this technique the electrodes are placed on each of two separate 
muscles or muscle groups 
- Reciprocal: The active electrode is placed on two separate muscles or muscle groups, 
either agonist or antagonist, or bilaterally, with the indifferent electrode place 
elsewhere just as in the case of the unipolar technique. 
- Interferential: With a minimum of four electrodes, they are placed in crossed pattern 
over the target area, around 4 to 6 inches apart. The cruciate pattern may also be 
three-dimensional (lateral/posterior/medial), as in the case of knee or shoulder joints. 
- Trans-Arthral: The electrodes are placed on two sides of the target joint. Current is 
not to pass across the joints, but flows around the joint between the electrodes.  
 
ELECTRICAL CHARACTERISTICS 
In conventional electrical stimulation for the management of pain, selective activation of Aβ 
fibres is targeted such that the impulse causes strong but comfortable paraesthesia, without 
muscle contraction. A continuous pulse pattern is used with frequency ranging between 10 
and 200 p.p.s,and pulse duration ranging between 100 and 200 µsec. Total duration of 
stimulation lasts for a minimum of 30 minutes.  The parameters we used in our study 
applying electrical tibial nerve stimulation for modifying spasticity were based on previous 
studies conducted on patients with spastic hemiplegia and have been specified in the section 
on Materials and Methods.  
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DECLINING RESPONSE TO ELECTRICAL STIMULATION 
Users have claimed that the effectiveness of electrical stimulation can decline over time, 
although the exact proportion of patients is unknown. With regard to pain relief, studies have 
shown patients reporting that the magnitude of pain relief from electrical stimulation may 
decline by around 40% over a period of one year. The decline can be due to multiple causes 
including weakening batteries, dysfunctional lead electrodes or worsening pain or spasticity. 
Patients havealso been reported to habituate to the stimulatory current owing to progressive 
failure of the nervous system to respond to a monotonous stimulus. 
 
CONTRAINDICATIONS 
1. Seizures: As it would be difficult to prove side-effects of stimulation as not being the 
cause of seizures, it is generally advised to avoid doing transcutaneous electrical 
stimulation among epileptic patients. 
 
2. Pregnant women in the first trimester are not advised to undergo electrical stimulation 
as there is a risk of inducing labour; administering electrical stimulation over the 
pregnant uterus is also not permitted in the management of labour pain. 
 
3. Patients with cardiac pace-setter as it could potentially interfere with the implanted 
electrical devices.      
 
4. Electrical stimulation should not be administered for the management of pain without 
a physician diagnosing the etiology and prescribing this modality. 
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5. Other areas of the body over which electrical stimulation should not be administered 
are as follows: 
a. The carotid sinus 
b. On broken skin 
c. Over dysaesthetic skin 
d. Over mucosal membrane such as within the mouth 
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MATERIALS & METHODS 
INCLUSION CRITERIA  
 All patients who had past history of a cerebrovascular accident and attending the weekly 
Stroke Clinic at our outpatient department were screened. Spasticity was graded according to 
the Modified Ashworth scale, specifically looking for clonus at the ankle joint of the paretic 
side of the body. Patients between the ages of 18 and 75 years, without any past history of 
cardiac arrhythmias, not using pacemakers or metal implants in the lower limbs were given 
informed consent forms. Pregnant women and patients with fixed flexion deformities or 
contractures involving the knee or ankle joints were also excluding during the screening 
process; Patients consenting to join the study were then directed to the physiotherapist who 
would administer the posterior tibial nerve stimulation. 
 
SAMPLE SIZE CALCULATION  
The sample size was calculated based on the results of a study on the relief of spasticity using 
electrical stimulation in patients who had past history of a cerebrovascular accident. A sample 
size of 24 with 12 in the sham arm and 12 in the active arm were needed to detect a 
difference of 30 units in the H/M ratio with a standard deviation of 31.8 and 20.5 in the active 
and sham arms respectively. The sample size was calculated for an error of 5% and power of 
80%.  
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STUDY DESIGN 
This was a randomized controlled study conducted on in-patients as well as patients attending 
our weekly stroke clinic, with history of a cerebrovascular accident including ischemic and 
hemorrhagic strokes as well as cortico-venous thrombosis. Patients were recruited over an 
eighteen month period between April 2013 and August 2014. On an average, around 25 
patients would attend each weekly clinic conducted for patients who had survived a 
cerebrovascular accident. These patients were screened by physicians for ankle clonus and 
spasticity of the gastrosoleus muscle on the paretic half of their body. After an informed 
consent was taken, a physician would take a detailed history and record data as per the 
proforma shown in appendix 1. A baseline recording of H/M ratio was also taken at this 
stage. Subsequently, patients were assigned by a physiotherapist into one of two groups (A) 
or (B) based on the randomized allocation, concealed in a sealed envelope given to the 
patient. The physiotherapist would then administer the electrical stimulation to the posterior 
Tibial nerve on the paretic lower limb via 2 adhesive patch electrodes attached behind the 
medial maleolus as shown the figure below. The anode was denoted by the patch attached to 
a black wire and stuck 2 centimetres proximal to the cathode denoted by the patch attached to 
a red wire. The electrical stimulus was delivered from a device connected to the patch 
electrodes by one of two wires marked A or B. Neither the physiotherapist nor the physician 
performing the H/M Ratio knew whether wire A or wire B was active. The stimulation was 
administeredover a period of 20 minutes on a daily basis for 2 weeks.   
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RANDOMIZATION OF PATIENTS 
Randomization was done using computer generated random number allocation, placing 
patients in one of 2 groups (A or B) – the control group receiving the standard protocol of 
stroke rehabilitation and the intervention group receiving additional PTNS. Standard protocol 
of stroke rehabilitation in our department consists of 4 hours each of physiotherapy and 
occupation therapy and when necessary, additional speech therapy. Neither the investigator 
responsible for randomized allocation of patients, nor the physiotherapist administering the 
stimulation were aware of which group was receiving active and which group the sham 
stimulation.  
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   25 PATIENTS RECRUITED 
 
 
 
SHAM STIMULATION ARM       ACTIVE STIMULATION ARM 
(BASELINE H/M RATIO DONE)     (BASELINE H/M RATIO 
DONE) 
13        12 
 
 
 
PATIENTS EVALUATED  DROP OUT PATIENTS EVALUATED   DROP OUT 
COMPLETELY   PATIENTS  COMPLETELY   PATIENTS 
11       2     9     3 
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INTERVENTION 
The electrical stimulator was indigenously made by the Department of Bioengineering in our 
institution with the parameters of stimulation being a pulse width of 200 microseconds 
(µsec), frequency ranging between 32 Hz, and a supra-threshold intensity ranging 
between 2 and 100mA of current. This stimulus was applied by an assigned 
physiotherapist, just posterior to the pulsatile Posterior Tibial artery, located behind the 
medial malleolus of the spastic lower extremity. The stimulation was administered through a 
wire connecting the stimulator to adhesive electrodes applied to the afore-mentioned location 
on the paretic lower limb. One of two wires coded 1/A or 2/B were used to connect the 
adhesive skin-electrodes to the stimulator. The sham wire was internally disconnected and 
information of which of the two wires was the sham wire, was only divulged at the end of the 
data collection, at the time of analysis. 
The current from the CMC-DAQ (Data Acquisition System) electrical stimulator were 
delivered at the posterior tibial nerve using self-adhesive pad electrodes (50x50 mm, made by 
Sunrise). Polarity of the electrode placement was marked at the beginning of the period of 
stimulation. (i.e. cathode posterior to the medial malleolus). 
Patients in both groups underwent 20 minutes of stimulation per session, once a day for 2 
weeks. Simultaneously they continued the standard in-house protocol which constitutes 4 
hours each of physiotherapy and occupation therapy. Patients who required speech therapy 
spent a stipulated amount of time with the speech therapist as well. A history of medications 
taken prior to and during the time of stimulation were noted although none of them were 
stopped.  
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Figure 7 Indigenous Electrical Stimulator 
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Figure 8 Administering Electrical Stimulation to the Posterior Tibial Nerve 
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MEASUREMENT OF H/M RATIO: 
The machine and software used to obtain the values of H/M Ratio was the Synergy range of 
multimedia EMG/EP systems designed and manufactured by VIASYS Healthcare UK Ltd, 
Manor Way, Old Woking Surrey, GU22 9JU United Kingdom. The bandpass filter of the 
machine was set at 3 Hz to 3 kHz. Amplified signals obtained during the test were digitised 
and stored in the hard disk of the computer for calculation of the H-max: M-max ratio. 
To obtain the H/M Ratio, we placed subjects in a prone position and the feet suspended over 
the end of the bed and the head resting on a pillow.  A surface bar-electrode (Medelec 
Synergy) with the cathode end facing distallywas placed over the bulk of the Soleus muscle. 
We prepared the electrode sites by shaving the skin and preparing it with conducting gel. A 
reference ground electrode was placed 5 centimetres below the Popliteal crease.  
The Soleus H-Reflex was elicited by stimulating the tibial nerve in the Popliteal fossa. A 
hand-held electrode was used to locate the optimum point for nerve stimulation. This motor 
point of stimulation was determined by its propensity to yield the largest M wave amplitude 
during low-intensity stimulation. The nerve stimulus was a 1millisecond monophasic square 
pulse generated by a constant current stimulator. Initially the optimal location for Tibial nerve 
stimulation in the popliteal fossa was determined by re-positioning the stimulating electrode 
around till a contraction of the gastrocnemius muscle was clearly visible. The current was 
subsequently gradually increased till an H reflex was recorded. Rejecting the other values, 
only the largest amplitude obtained was selected as the H-max. The H reflex was identified 
by the emergence of a triphasic wave with a small positive deflection followed by a larger 
negative deflection.  
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We analyzed the H-Reflex responses by measuring the peak-to-peak amplitude. The stimulus 
intensity was gradually increased from a level below the H-Reflex or M wave threshold to 
one capable of eliciting the maximal M wave amplitude. The M wave was analysed by 
measuring the baseline to peak amplitude. The ratio of the H-max and M-max values was 
calculated by dividing the maximum amplitude of the H reflex by that of the M wave.  
 
 
Figure 9 Measurement of H/M Ratio 
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Figure 10 Placement of electrodes and stimulator in measuring H/M Ratio 
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STATISTICAL ANALYSIS   
The data analysis was done using STAT software version 13. The descriptives are provided 
with the median along with a range for continuous variables, as the data is skewed. The 
categorical variables were presented with frequency along with percentage.  
The pre and post intervention differences in both groups were analyzed using Wilcoxin 
signed rank test. The percentage change among the two groups was compared using the 
Mann-Whitney u test. 
The baseline characteristics were analysed among the two groups using the Fisher‟s exact test 
if the variable was categorical, and if the variable was continuous, the Mann-Whitney u test 
was used. 
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RESULTS 
The various parameters of subjects recruited were analysed among the two groups in the 
study. Group 2 received active stimulation to relieve spasticity and group 1 received the sham 
stimulation. 
Factors that are likely to influence the spasticity were compared between the two groups and 
included demographic characteristics as well as factors that are known to worsen spasticity. 
Demographic characteristics compared included the following: 
There were 11 patients in the stimulation arm 9 in the control or sham group. Although more 
males were recruited in the sham group, based on the Fisher‟s exact test, the gender of 
subjects in each group was found to be insignificant as per the Fisher‟s exact test. (p=0.056) 
(Table 1.) 
Table 1. Gender distribution of patients enrolled in the study 
GENDER ACTIVE 
INTERVENTION 
ARM  
(No. ; %) 
SHAM GROUP 
(No. ; %) 
TOTAL 
MALE 10 ; 90.9 5 ; 55.55 15 ; 75 
FEMALE 1;  9.09 4 ; 44.44 5 ; 25 
TOTAL 11 ; 100 9 ; 100 20 ; 100 
P = 0.056 
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The aetiology of cerebrovascular accident among the recruited patients was compared 
between the active intervention and sham stimulation groups. The percentages of patients 
with thrombotic strokes were 54.5 and 66.6 percent, while those with hemorrhagic strokes 
were 27.27 and 11.11 percent respectively among the sham stimulation and active 
intervention groups. The percentages of patients in each group with cerebral venous 
thrombosis were comparable at 18.18 and 22.22% and were hence not significantly different.  
 
Table 2. Etiology of cerebrovascular accidents among Patients 
DIAGNOSIS SHAM 
STIMULATION 
ARM 
(No. ; %) 
ACTIVE 
INTERVENTION 
ARM 
(No.; %) 
TOTAL 
 
(No. ; %) 
Infarct 6 ; (54.55) 
 
6 (66.67) 12 (60) 
Hemorrhage 3 ; (27.27) 
 
1 (11.11) 4 (20) 
CVT 2 ; (18.18) 
 
2 (22.22) 4 (20) 
TOTAL 11 ; (100) 
 
9 (100) 20 (100) 
(P-value: 0.66) 
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When comparing the trends of increase and decrease in spasticity as measured by the H/M 
Ratio, there was no significant change noticed based on the aetiology of the cerebrovascular 
accident. 
Table 3. Comparison of H/M Ratios based on aetiology of cerebrovascular accident 
Diagnosis ACTIVE 
INTERVENTION 
ARM 
Total SHAM 
STIMULATION 
ARM 
Total 
 Patients 
with 
Increase 
in H/M 
Ratio 
No. ; (%) 
Patients 
with 
Decrease 
in H/M 
Ratio 
No. ; (%) 
 Patients 
with 
Increase 
in H/M 
Ratio 
No. ; (%) 
Patients 
with 
Decrease 
in H/M 
Ratio 
No. ; (%) 
 
 
Infarction 2 (66.67) 
 
4 (66.67) 6 
(66.67) 
2 (40) 4 (66.67) 6 (54.55) 
Hemorrhage 0 
 
1 (16.67) 1 
(11.11) 
2 (40) 1 (16.67) 3 (27.27) 
CVT * 1 (33.33) 
 
1 (16.67) 2 
(22.22) 
1 (20) 1 (16.67) 2  (18.18) 
TOTAL 3 (100) 
 
6 (100) 9 (100) 5 (100) 6 (100) 11 (100) 
*CVT: Corticovenous Thrombosis 
 
Only one patient in the intervention group had reached the hospital within the stipulated time 
to receive thrombolysis. Surgical management of the cerebrovascular accidents among the 
recruited patients were not significant with 16.67 % and 20% among each of the study arms. 
The baseline characteristics of risk factors contributing to the development of cerebrovascular 
accidents were compared. The most common risk factors contributing to the development of 
cerebrovascular accidents include smoking, Type II Diabetes Mellitus, hypertension, 
underlying vasculitis, elevated Homocysteine levels, carotid artery disease, ischemic heart 
disease andvalvular heart disease.A significant difference in the presence of these risk factors 
among the patients in each study arm was not detected, as evident in the Table 4. 
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Table 4. Intrinsic Risk Factor Profile of Study Patients for CVA  
Risk Factor Active Stimulation 
Arm 
Number, (%) 
Sham Stimulation 
Arm  
Number, (%) 
 
P-value 
Type II Diabetes 2,(22.22) 3,(27.27) >0.99 
Hypertension 4,(44.44) 5,(45.45) >0.99 
Vasculitis 0 0 - 
Homocysteinemia 2,(36.36) 2,(22.22) 0.64 
Carotid Disease 3,(33.33) 5(50) 0.65 
Ischemic Heart 
Disease 
1(12.5) 0 0.42 
Valvular Heart 
Disease 
1(12.5) 0 0.42 
 
 Seizures as a complication of cerebrovascular disease could have a bearing on the 
management of spasticity. Many commonly used anti-epileptic drugs like Benzodiazepines 
are known to also reduce spasticity.Among the two patients in the active groups and 3 in the 
sham group had a history of seizures and were on AED. These medications were not changed 
during the course of the study. Seizures were not observed as an adverse effect following the 
initiation of electrical stimulation as an intervention in our study. 
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Table 5. Change in outcome measures based on presence of seizures  
Change in 
H/M Ratio 
(Level of 
Spasticity) 
ACTIVE 
INTERVENTION 
ARM 
(No. ; % ) 
TOTAL SHAM 
STIMULATION ARM 
(No. ; % ) 
TOTAL 
 SEIZURES 
ABSENT 
SEIZURES 
PRESENT 
 SEIZURES 
ABSENT 
SEIZURES 
PRESENT 
 
DECREASED 3 (42.86) 0 3 (33.33) 3 (37.50) 2 (66.67) 5 (45.45) 
INCREASED 4 (57.14) 2 (100) 6 (66.67) 5 (62.50) 1  (33.33) 6 (54.55) 
TOTAL 7 (100) 2 (100) 9 (100) 8 (100) 3 (100) 11 (100) 
 
Factors contributing to the worsening of spasticity were also analysed with regard to the 
response to electrical stimulation.While there were 2 people in the sham stimulation group 
who had urinary cultures showing urinary infection after diagnosis of the cerebrovascular 
accident was made, none of the patients in the active intervention group had previous 
evidence of a urinary tract infection. While none of the patients in the active intervention 
group were found to have radiological evidence of heterotopic ossification (HO) or deep vein 
thrombosis (DVT), in the sham stimulation group, one patient was found to have HO and one 
had developed DVT. In-grown toe-nails and urinary tract calculi were the other factors that 
were screened for among the recruited patients, known to develop worsening of spasticity. 
However these two factors were observed in neither the sham stimulation, nor the active 
intervention arms of the study.   
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Table 6. Profile of Risk Factors for Development of Spasticity among study patients 
Risk Factor Active Stimulation 
Arm 
Number, (%) 
Sham Stimulation 
Arm 
Number, (%) 
P-value 
Urinary Tract 
Infection (UTI) 
0 3,(72.73) 0.21 
Urinary Tract 
Calculi 
0 0 - 
Heterotopic 
Ossification 
 1,(9) >0.99 
Deep Vein 
Thrombosis 
0 1,(10) >0.99 
In-grown toe nails 0 0 - 
 
As urinary tract infections and heterotopic ossification were the only major risk factors for 
spasticity that were observed among patients in the two arms of the study, they were analysed 
for any effect they might have had on the levels of spasticity after 2 weeks of electrical 
stimulation. The results of the analyses are as shown in the tables below, showing that neither 
heterotopic ossification nor urinary tract infections had any significant effect on the change in 
spasticity (as manifested by H/M Ratio) after the two weeks of intervention. 
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Table 7. Effect of Heterotopic Ossification on spasticity, following the 2 week intervention 
 
Change in 
H/M Ratio 
(Level of 
Spasticity) 
 
ACTIVE 
INTERVENTION 
ARM 
(No. ; % ) 
 
TOTAL 
 
SHAM 
STIMULATION 
ARM 
(No. ; % ) 
 
TOTAL 
  
H.O* 
ABSENT 
 
H.O* 
PRESENT 
  
H.O* 
ABSENT 
 
H.O* 
PRESENT 
 
DECREASED 3 (33.33) 0 3 (33.33) 4 (40) 1 (100) 5 (45.45) 
INCREASED 6 (66.67) 0 6 (66.67) 6 (60) 0 6 (54.55) 
TOTAL 9 (100) 0 9 (100) 10 (100) 1 (100) 11 (100) 
*H.O: Heterotopic Ossification 
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Table 8. Effect of Urinary Tract Infection on spasticity, following the 2 week intervention 
 
Change in 
H/M Ratio 
(Level of 
Spasticity) 
 
ACTIVE 
INTERVENTION 
ARM 
(No. ; % ) 
 
TOTAL 
 
SHAM 
STIMULATION 
ARM 
(No. ; % ) 
 
TOTAL 
  
UTI* 
ABSENT 
 
UTI* 
PRESENT 
  
UTI* 
ABSENT 
 
UTI* 
PRESENT 
 
DECREASED 3 (33.33) 0 3 (33.33) 3 (37.50) 2 (66.67) 5 (45.45) 
INCREASED 6 (66.67) 0 6 (66.67) 5 (62.50) 1 (33.33) 6 (54.55) 
TOTAL 9 (100) 0 9 (100) 8 (100) 3 (100) 11 (100) 
*UTI: Urinary Tract Infection 
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Medications commonly prescribed to manage spasticity were also screened among the 
recruited patients. Three people in the sham group and two in the active intervention group 
were using Baclofen; one person in the active intervention group was using Tizanidine while 
one person each in the active intervention and sham groups were using Benzodipine. The 
dosages of these medications were not changed during the course of the study. The number of 
patients using anti-spastic medication in each arm did not render any statistically significant 
difference between them.  
Table 9. Profile of medications used for control of Spasticity among study patients 
Medication Active Stimulation 
Arm 
Number, (%) 
Sham Stimulation 
Arm 
Number, (%) 
P-value 
Benzodiazepine 
 
1(11.11) 1,(10) >0.99 
Baclofen 1,(11.11) 3(30) 0.58 
Tizanidine 0 0 - 
 
As Diazepam and Baclofen were the only major two drugs used to alleviate spasticity among 
patients in the two arms of this study, they were analysed for any effect they might have had 
on the levels of spasticity after 2 weeks of electrical stimulation. The results of the analyses 
are as shown in the tables below showing that neither Baclofen nor Diazepam had any 
significant effect on the change in spasticity (as manifested by H/M Ratio) after the two 
weeks of intervention. 
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Table 10. Effect ofBaclofen on spasticity, following the 2 week intervention 
Change in 
H/M Ratio 
(Level of 
Spasticity) 
BACLOFEN IN  THE 
ACTIVE 
INTERVENTION 
ARM 
(No. ; % ) 
TOTAL BACLOFEN IN THE 
SHAM 
STIMULATION 
ARM 
(No. ; % ) 
TOTAL 
 ABSENT PRESENT  ABSENT PRESENT  
DECREASED 3 (37.50) 0 3 (33.33) 2 (28.57) 2 (66.67) 4 (40) 
INCREASED 5 (62.50) 1 (100) 6 (66.67) 5 (71.43) 1 (33.33) 6 (60) 
TOTAL 8 (100) 1 (100) 9 (100) 7 (100) 3 (100) 10 (100) 
 
Table 11. Effect of Diazepam on spasticity, following the 2 week intervention 
CHANGE IN 
THE H/M 
RATIO 
(Level of 
Spasticity) 
DIAZEPAM IN THE 
ACTIVE 
INTERVENTION 
ARM 
(No. ; % ) 
TOTAL DIAZEPAM IN THE 
SHAM 
STIMULATION 
ARM 
(No. ; % ) 
TOTAL 
 ABSENT PRESENT  ABSENT PRESENT  
DECREASED 3 (37.50) 0 3 (33.33) 4 (44.44) 0 4 (40) 
INCREASED 5 (62.50) 1 (100) 6 (66.67) 5 (55.56) 1 (100) 6 (60) 
TOTAL 8 (100) 1 (100) 9 (100) 9 (100) 1 (100) 10 (100) 
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Ankle foot orthoses with wedges which maintain the toes in dorsiflexion have been known to 
decrease spasticity. While fifty percent of the patients in the sham stimulation used ankle foot 
orthoses, only twenty percent in the active stimulation group used the same. Among the 
patients in whom there was a decrease in spasticity manifested by a decrease in H/M ratio, 
40% wore an AFO on the paretic limb in the sham stimulation arm while only 33% of the 
patients in the active stimulation arm were using an AFO. 
The various etiological factors in the development of a cerebrovascular event and factors 
which are responsible for worsening spasticity among patients with stroke were screened for 
among the active stimulation and the intervention group. However, the number of patients in 
which these factors were present has not caused any statistically significant difference in the 
baseline characteristics of the two groups.  
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Figure 11 Percentage Change of H/M Ratio in Sham and Active Stimulation Arms 
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The descriptive in the graph above were presented as frequency percentages and analysed 
using Fisher‟s exact test. The percent change in the sham arm has a wider range compared to 
the active intervention arm. For the sham arm, the median percentage increase after the 
intervention is 7.46% while in the active intervention group, it is 27.87%, where the 
difference between the two arms is not statistically significant (p=0.38) 
 
 
Figure 12 Comparison of Pre and Post-Intervention H/M Ratios in the Sham & Active 
Stimulation Groups 
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Comparison of the change in spasticity was done using measurement of H/M ratios at the 
time of recruitment and also after two weeks of intervention. The values of the change in 
H/M ratios were highly skewed, and since the number of patients in each arm was small, a 
two-sample Wilcoxon sign rank-sum test was used to compare the two arms. As 
demonstrated in the graph above, change in the median H/M ratio value from pre-intervention 
(0.72) to post-intervention (0.56) within the sham arm was not statistically significant 
(p=0.62). Likewise the change in the median H/M ratio value from pre-intervention (0.52) to 
post-intervention (0.53) in the active intervention arm was also not statistically significant 
(p=0.10). 
With regard to the Modified Ashworth Scale scores, clonus which was observed prior to 
starting the intervention was observed even after the two weeks of electrical stimulation. 
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DISCUSSION 
This study was undertaken to observe the effect of a non-pharmacological, non-invasive 
method to decrease spasticity following a cerebrovascular accident. Earlier studies have 
shown the beneficial effects of electrical stimulation. In this study, a portable device 
delivering a stimulus with a pulse width of 200usec, frequency of 40Hz and the intensity 
ranging between 0-100 mA, based on the patient‟s pain tolerance. These parameters can be 
set into a hand-held device designed by the Department of Bioengineering, Christian Medical 
College, Vellore. The adjustments to settings can be easily taught to patients, enabling them 
to administer this form of therapy themselves. The point of stimulation, namely the course of 
the Posterior Tibial Nerve just behind the medial malleolus where it is most superficial, can 
also be easily located by patients or their care-takers for administering the stimulation. 
The idea of using electrical stimulation of peripheral nerves as a means of modulating spinal 
excitability has been propounded in earlier studies. Levin and Hui-Chan had performed 
studies comparing the effects of active electrical stimulation versus placebo stimulation on 
the common peroneal nerve of spastic hemiparetic patients. Numerous studies have been 
done on electrical stimulation of a peripheral nerve to reduce spasticity in the detrusor muscle 
of the bladder, including one within our own institution (77) . The study by Levin et al 
demonstrated significant benefits with repeated application of electrical stimulation. 
Although patients in this study also underwent 15 days of electrical stimulation, the duration 
of the therapy session itself was longer, with each lasting 60 minutes compared to 30 minutes 
used in our study protocol.  
Spasticity was evaluated in this study by both a clinical scale and an electrophysiological test. 
While it is the most widely used clinical assessment of spasticity, the Modified Ashworth 
Scale (MAS) has been shown to have much inter-rater variability and hence the need arose 
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for a more objective test. The H-reflex is known to be a reflexion of spinal anterior horn cell 
excitability and was hence the H/M ratio has been utilized to objectively measure spasticity 
which is determined by the level of spinal excitability. Clinically, patients in both arms were 
found to have spasticity in the form of ankle clonus, even after the two weeks of electrical 
stimulation. While the H/M ratio was not found to decrease in all the patients studied, there 
was no statistically significant improvement in the H/M ratios. 
Electrical stimulation was offered as an additional mode of therapy supplementing the 
standard therapy. Patients were also expected to continue anti-spastic medication that they 
were taking prior to being enrolled in the study. There was no significant difference between 
the groups in terms of the number of patients on anti-spastics, namely Benzodiazepine 
(p>0.99) and Baclofen (p=0.58) at the beginning of the study. While Tizanidine is another 
commonly used anti-spastic, none of the patients enrolled in our study used this drug. All of 
the three above mentioned drugs act via pathways in the central nervous system and the 
decision to not stop the drugs was to ensure that the prior use of an anti-spastic would not 
become a confounding factor in the outcomes measured at the end of two weeks of electrical 
stimulation.  
The various factors known to aggravate spasticity were evaluated at the time of enrolment to 
ensure that there was homogeneity between the two groups. There was no statistically 
significant difference between the groups in terms of factors likely to worsen spasticity. 
These factors hence had no bearing on the effect of the electrical stimulation as observed in 
the decrease in H/M ratios 
Spasticity is also known to worsen with increasing duration from the onset of hemiplegia. 
This is further aggravated when other complications set in, such as heterotopic ossification, 
urinary tract infection and deep vein thrombosis, which in turn affect spasticity.  However, in 
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our study, there was no difference between the active intervention and the sham arms of the 
study with regard to the mean duration of hemiplegia from the onset of the cerebrovascular 
accident to the time of initiating electrical stimulation.  
Other baseline characteristics evaluated were gender, prior history of seizures and 
interventions for management of the cerebrovascular accident that may have had a bearing on 
the level of spasticity and the response to treatment. While the sham arm of the study did not 
have any women, the active intervention group had an equal distribution of both genders. 
However while analysing the decrease in spasticity as measured by a decrease in the H/M 
Ratio, no significant difference was found between male and female patients. Prior history of 
seizures was also considered in the evaluation of those patients who had a drop in the H/M 
Ratio following the two weeks of electrical stimulation. Seizures have not been found to 
increase the level of spasticity; however, patients may be subsequently started on medications 
such as benzodiazepines for seizure prophylaxis.Medicines such as benzodiazepines which 
are used for management of seizures may also act on centrally acting neurotransmitters such 
as Gamma Amino Butyric Acid (GABA) which may affect the level of spasticity in patients. 
On taking a history of drugs used for seizure-prophylaxis among the three patients in the 
sham arm and two patients in the active intervention arm, all of them were on oral Phenytoin 
and in some cases, Leviteracetam was also being used. These drugs were also not stopped 
during the two-week course of the study. However, these drugs are not known to affect 
spasticity and this in turn corroborates with the lack of significant difference in the levels of 
spasticity and reduction of the same with the posterior tibial nerve stimulation. Other 
interventions immediately following the cerebrovascular accident include thrombolysis and 
surgery. The early detection of infarcts and thrombolysis within the permissible time frame of 
four hours would definitely have an impact on the overall outcome of the patient. We 
evaluated the effect of electrical stimulation on those patients who had undergone 
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thrombolysis and whether there was any supplementary benefit on the levels of spasticity. 
There was neither a significant difference in the numbers of patients in each of the study arms 
who had undergone thrombolysis, nor was there any significant difference in the 
improvement of levels of spasticity among those who underwent both thrombolysis as well as 
electrical stimulation. Only two patients in each of the study arms had undergone surgery 
following onset of the cerebrovascular accident. Surgery in the event of raised intra-cranial 
tension following the cerebrovascular accident, would also improve the over-all survival 
outcome. The raised intracranial tension, for which surgery was indicated, also did not show 
any effect on the baseline levels of spasticity among the patients who required surgical 
intervention. There was no significant decrease in the level of spasticity among those who 
underwent surgery among patients in either arm of the study.  
Underlying diseases among the patients such as diabetes were also considered in their effect 
on the outcome following spasticity as measured by the H/M ratio. Although no formal 
assessment of nerve conduction was conducted on the Posterior Tibial Nerve on the paretic 
side of the study patients, the effect of peripheral neuropathy on conduction may have a 
bearing on the efficacy of electrical stimulation. Only three out of eleven (22.2%) patients in 
the sham arm and two out of nine (27.2%) patients in the active intervention were known to 
have diabetes mellitus as an underlying risk factor for a cerebrovascular accident. These 
numbers did not contribute significantly to any change in the baseline characteristics of the 
two arms that might have had a confounding effect on the efficacy of the electrical 
stimulation. 
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Limitations of the study and Scope for Further Studies 
This study was conducted with the primary objective of evaluating if electrical stimulation 
with a reasonably priced device which was affordable and easily portable for patients could 
have an added benefit in the management of spasticity. If patients could be further segregated 
based on prior use of anti-spastic medication, a cost-effectiveness study could also have been 
done to assess any monetary advantage that the device delivering electrical stimulation might 
have over the anti-spastic drugs.  
The other benefit that electrical stimulation was speculated to have over anti-spastic 
medicines was that of avoiding the sedative effects of the latter. The sedative adverse effects 
of anti-spastic medication have been known to decrease compliance with scheduled 
physiotherapy and in carrying out activities of daily living. This in turn can have a bearing on 
the overall quality of life of a patient.  No formal assessment of levels of sedation, 
participation in activities of daily living or compliance with scheduled physiotherapy was 
compared in this study between patients receiving electrical therapy versus those receiving 
anti-spastic medication alone. Studying the above-mentioned benefits of electrical stimulation 
over anti-spastic medication was beyond the scope of this study as ethical clearance was not 
obtained for the withdrawal of anti-spastic medication in patients with spastic hemiplegia.  
The objective measure of spasticity we chose in this study was the H/M ratio. Levin and Hui-
Chan in their study on the effect of electrical stimulation on spasticity in hemiplegic patients 
also did not see a significant effect on the H/M ratio, despite a decreasing trend in the same 
after 2 weeks of this therapy. However a variation on the H/M ratio, namely the vibration 
inhibition index (Hvib/Hctl ratio) did detect a significant trend after two weeks of electrical 
stimulation of the peripheral nerve. As a significant change in H/M ratio was not detected in 
our study, we speculate whether the conducting the vibration inhibition index on the patients 
99 
 
in our study may have detected a significant change in levels of spasticity. The vibration 
inhibition index which requires the measurement of the H-reflex while a vibratory stimulus is 
applied over the tendon of the spastic muscle (in this case, the Achilles tendon), was not 
conducted in our study due to technical constraints. 
Duration of electrical stimulation both in terms of the number of days of stimulation as well 
as that per session might not have been sufficient in this study. The studies conducted by 
Levin and Hui-Chan scheduled 45 minutes and 60 minutes each over a period of 15 days. In 
our study, we wanted to evaluate the effect of half an hour of stimulation which might 
increase compliance among patients and their care-takers who have limited time in a session 
of physiotherapy. Shorter sessions of stimulation if equally efficacious would be more 
beneficial in a tertiary hospital set-up where therapists have large numbers of patients to fit 
into their daily schedules. Further studies may be required to determine the minimum 
effective duration per session of electrical stimulation to bring about significant decrease in 
spasticity levels. 
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CONCLUSION 
This study was conducted with the intention of evaluating the neuromodulatory effect of 
electrical stimulation on the hyper-excitable state observed in patients with spastic 
hemiplegia following a cerebrovascular accident. The results of the electrophysiological test, 
namely the Hmax:Mmax ratio used to measure the levels of spasticity have not shown any 
significant difference following the 2 weeks of electrical stimulation. Based on these results 
and those of studies conducted earlier on electrical stimulation as a means of alleviating 
spasticity in the hemiplegia, we conclude that the parameters of stimulation followed were 
inadequate. The duration of stimulation will need to be increased while further studies will be 
required to determine if changes in parameters such as pulse width, pulse frequency and type 
of stimulation are also necessary to bring about a significant decrease in spasticity. 
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PATIENT INFORMATION SHEET 
 
Title of the study: 
 A randomised control trial to observe the efficacy of proposed Transcutaneous Tibial Nerve 
Stimulation against standard treatment on gastrosoleus spasticity in patients with traumatic 
brain injury or cerebrovascular accidents. 
 
Principal Investigator: Dr. Rahul Jacob Thomas 
Department: Physical Medicine & Rehabilitation (PMR), CMC, Vellore 
Spasticity is a condition where there is damage to the central nervous system, namely the 
brain and the spinal cord, which results in increased tone of muscles and tightness of joint 
movements. The increased tone in the feet cause the affected foot or both feet to point 
downwards and this in turn can affect the ability to stand or walk with stability. While there 
are medicines that can be used to decrease spasticity, they also tend to have side-effects such 
as excessive drowsiness, which in turn can affect the progress in physiotherapy. While 
medicines tend to affect all muscles of the body, by electrical stimulation, only the key 
muscles selected will be acted upon. Electrical stimulation by the device made in our 
department could be a cost-effective alternative to those requiring expensive drugs to 
decrease the level of spasticity 
There are many ways to reduce the tightness in the muscles of the leg. We are trying to bring 
about that effect by providing electrical stimulation to a nerve that supplies the calf muscle, 
as it passes by the ankle joint. As the nerve can be easily stimulated in this region, we hope 
that it will send signals to the higher control centres in the body to reduce the tightness in the 
legs. 
There are many ways of measuring the amount of spasticity present in a given part of the 
body.  One of the most common ways is a grading scale known as the Modified Ashworth 
Scale. However, this does not give a precise quantifiable measure of the spasticity. 
Electromyography is a method understanding properties of muscles based on their reaction to 
external stimulation of the nerves supplying them. Spasticity of the calf muscle can be 
studied by stimulating the Tibial Nerve as it passes through the diamond shaped area at the 
back of the knee. The reaction of the muscle is recorded by sensors connected to a computer, 
when it is stimulated by passing an electrical stimulus over the Tibial nerve. You may 
experience some discomfort while the external stimulation of the Tibial Nerve is being 
conducted. 
The PMR Department of CMC is conducting a study using electromyography to measure the 
amount of spasticity present in patients using electrical stimulation This will be conducted 
among patients with head injuries, who might have spasticity in muscles of both the lower 
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limbs and among patients who have had a stroke and have spasticity only on one half of the 
body.   
If you are willing to be part of the study, you will be required to: 
 
- Undergo a clinical examination to assess any additional 
factors contributing to spasticity in your legs. 
 
 
- Undergo a clinical assessment of level of spasticity, 
followed by the electromyography test explained 
above to get a quantifiable assessment of the spasticity 
in your legs. 
 
- Have an electrical stimulator attached to your ankle for 
30 minutes, once a day, over a period of 14 days. 
 
 
- Undergo a second clinical and electromyography 
assessment of the spasticity in your legs. 
   
Participation in this study is not likely to cause harm to your health in any foreseeable 
manner. Electromyography is a standard test of studying muscle properties. You could be 
part of one of two groups – one in which the electrical stimulator will be active and in the 
other, a sham electrical stimulator which does not deliver any electrical stimulus will be used. 
If you do not want to participate in this study, you are free to say so. You can choose to 
withdraw from the study at any time without being obliged to provide an explanation. This 
will not affect the treatment you receive in this hospital in any way. 
If you need additional information, you are welcome to contact us and the contact 
information is provided below. Additional information on electrical stimulation and the 
electromyography test will be provided on request. 
Dr. Rahul Jacob Thomas 
Department of PMR 
CMC Hospital 
Vellore, Tamil Nadu-632004 
Phone: +91-8870003550 
E-Mail: rjthomas@cmcvellore.ac.in 
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INFORMED CONSENT 
 
Title of the study: A randomised control trial to observe the efficacy of proposed 
Transcutaneous Tibial Nerve Stimulation against standard treatment on gastrosoleus 
spasticity in patients with traumatic brain injury or cerebrovascular accidents. 
Principal Investigator: Dr. Rahul Jacob Thomas 
Department: Physical Medicine and Rehabilitation (PMR), CMC, Vellore 
 
I, ________________ have understood the details of the proposed study. The following 
aspects of the study have been explained to me in a comprehensible manner: 
 
1. If I give consent to participate in this study, I will be willing to undergo electrical 
stimulation of the posterior tibial nerve and the tests to assess the level of 
spasticity in my lower limbs 
 
2. It has been explained to me that I may be in one of two groups, one of which will 
receive stimulation, and the other in which a sham stimulator will be used. 
 
3. Usage of stimulator is not likely to adversely affect my health in any foreseeable 
manner. 
 
4. I can choose not to give consent to be part of this study. I can also choose to 
withdraw myself from the study at any time without being obliged to provide an 
explanation. In any case, my decision will not affect the treatment given to me in 
this hospital. 
 
I am willing to give consent to be part of this study voluntarily and without any coercion 
from the investigators of this project. 
 
 
Signature of patient                                                                   Signature of investigator 
 
Signature of witness 
Date: 
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DATABASE WITH THE MAIL RESULTS 
DOI Date of Stroke 
No. of Past 
(Y/N)Strokes 
Time Since Last 
Stroke (Months) 
Current 
Diagnosis 
Side of 
Lesion(R/L/B) Duration (days)  Admit Dt. Tardeiu I (X,Y) MAS Gr. I 
H-Amp (I) 
(uV) M-Amp (I) (uV) H/M (I) (%) Hvib/Hctl(I) (%) ES Start Dt 
ES End Dt Tardeiu II (X,Y) MAS Gr.II H-Amp (II) (uV) 
M-Amp (II) 
(uV) 
H/M (II) (%) 
Hvib/Hctl(II) 
(%) Diabetes(Y/N) Hypertension(Y/N) Vasculitis(Y/N) 
Smoking (Y/N) UTI(Y/N) H.O(Y/N) DVT(Y/N) 
In-Grown Toe-
Nails(Y/N) 
Diazepam(Y/N) Tizanidine(Y/N) Baclofen(Y/N)     
 
  
 
Pre Post 
ID 
NUMBER 
STUDY 
ARM 
Hmax(p-
p) M-max H/M 
Hmax 
(p-p) M-max H/M 
651329D 1 1.5 2.23 0.672646 1.32 1.81 0.729282 
902057F 2 1.06 2.98 0.355705 1.09 2.05 0.531707 
207804F 1 1.45 6.02 0.240864 1.42 2.5 0.568 
904212F 2 0.57 3.7 0.154054 0.8 4.93 0.162272 
878348F 1 0.67 4.28 0.156542 1.16 3.4 0.341176 
882335F 2 1.09 1.76 0.619318 1.25 1.48 0.844595 
880495F 1 2.07 6.75 0.306667     #DIV/0! 
892134F 1 2 1.71 1.169591 2.83 2.07 1.36715 
895709F 2 1.07 1.29 0.829457     #DIV/0! 
898255F 1 1.94 3.05 0.636066 1.81 2.01 0.900498 
346483B 2 1.26 2.41 0.522822 2.11 3.11 0.678457 
530174D 1 1.27 6.36 0.199686 1.09 6.36 0.171384 
354470F 2 1.55 2.51 0.61753 2.44 3.11 0.784566 
001652F 1 1.37 1.35 1.014815 1.1 1.58 0.696203 
681695F 1 0.73 0.88 0.829545 2.3 2.5 0.92 
700453B 2 1.6 2.5 0.64 1.31 2.59 0.505792 
759186F 2 0.53 1.73 0.306358 1.44 5.32 0.270677 
899932C 2 0.78 1.66 0.46988 0.74 1.66 0.445783 
857065F 1 1.9 5.7 0.333333 1.5 5.71 0.262697 
843008F 2 2.88 4.61 0.624729 2.48 2.75 0.901818 
854107F 1 1.35 0.62 2.177419 1.18 2.48 0.475806 
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     Pre Trace 
 
Post Trace 
 
ID 
NUMBER 
STUDY 
ARM Date(I) 
Hmax(p-
p) M-max Date(II) 
Hmax 
(p-p) M-max 
651329D 1 6.MAY.14 4 11 23.MAY.14 7 15 
902057F 2 21.MAY.14 5 12 17.JUN.14 7 12 
207804F 1 30.MAY.14 12 18 12.JUN.14 13 18 
904212F 2 30.MAY.14 6 10 10.JUN.14 6 11 
878348F 1 24.JUN.14 11 18 12.JUL.14 6 11 
882335F 2 25.JUN.14 9 15 12.JUL.14 7 13 
880495F 1 1.JUL.14 7 17       
892134F 1 2.JUL.14 8 15 14.JUL.14 11 18 
895709F 2 9.JUL.14 9 18       
898255F 1 9.JUL.14 12 21 24.JUL.14 5 10 
346483B 2 23.JUL.14 13 19 7.AUG.14 13 19 
530174D 1 26.JUL.14 11 15 9.AUG.14 10 16 
354470F 2 24.MAR.14 25 28 11.APR.14 24 25 
001652F 1 24.MAR.14 9 18 15.APR.14 14 22 
681695F 1 28.MAR.14 9 15 13.APR.14 11 20 
700453B 2 10.APR.14 15 24 02.MAY.14 6 14 
759186F 2 10.APR.14 15 24 02.MAY.14 12 19 
899932C 2 7.MAY.14 11 18 30.MAY.14 8 17 
857065F 1 7.MAY.14 15 21 29.MAY.14 13 18 
843008F 2 7.MAY.14 5 15 31.MAY.14 7 13 
854107F 1 8.MAY.14 22 27 06.JUN.14 13 21 
 
